US20100004440A1 - Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same - Google Patents

Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same Download PDF

Info

Publication number
US20100004440A1
US20100004440A1 US12/585,229 US58522909A US2010004440A1 US 20100004440 A1 US20100004440 A1 US 20100004440A1 US 58522909 A US58522909 A US 58522909A US 2010004440 A1 US2010004440 A1 US 2010004440A1
Authority
US
United States
Prior art keywords
compound
methyl
amino
oxy
purin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US12/585,229
Other versions
US7723319B2 (en
Inventor
Dong-Gyu Cho
Jae-Hong Lim
Jae-Taeg Hwang
Woo-Young Cho
Hyun-Sook Jang
Chang-Ho Lee
Tae-Saeng Choi
Chung-Mi Kim
Yong-Zu Kim
Tae-Kyun Kim
Seung-Joo Cho
Gyoung-Won Kim
Jong-Ryoo Choi
Jeong-Min Kim
Kee-Yoon Roh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US12/585,229 priority Critical patent/US7723319B2/en
Publication of US20100004440A1 publication Critical patent/US20100004440A1/en
Application granted granted Critical
Publication of US7723319B2 publication Critical patent/US7723319B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/10Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Definitions

  • the present invention relates to an acyclic nucleoside phosphonate derivative represented by the following formula (1):
  • n denotes an integer of 1 or 2 and Y 1 represents O, CH 2 or N—R (R represents C 1 -C 7 -alkyl or C 6 -C 12 -aryl), which is useful as an antiviral agent (particularly, against hepatitis B virus), pharmaceutically acceptable salts, stereoisomers, and a process for the preparation thereof.
  • Purine or pyrimidine derivatives have anti-cancer and antiviral activities, and more than 10 kinds of the compounds including AZT, 3TC and ACV have already been commercialized. Particularly, since acyclic nucleoside phosphonate derivatives show a potent antiviral effect, cidopovir has been commercialized as an antiviral agent and many compounds including PMEA and PMPA now entered into the step of clinical trials. However, the earlier developed compounds were not perfect in the aspects of toxicity or pharmaceutical activity, and thus, it is still desired to develop a compound having no toxicity as well as a superior activity.
  • the prior researches for purine or pyrimidine derivatives or acyclic nucleoside phosphonate derivatives as reported heretofore are as follows.
  • Patents U.S. Pat. No. 5,817,647; U.S. Pat. No. 5,977,061; U.S. Pat. No. 5,886,179; U.S. Pat. No. 5,837,871; U.S. Pat. No. 6,069,249; WO 99/09031; WO96/09307; WO95/22330; U.S. Pat. No. 5,935,946; U.S. Pat. No. 5,877,166; U.S. Pat. No. 5,792,756; Journals: International Journal of Antimicrobial Agents 12 (1999), 81-95; Nature 323 (1986), 464; Heterocycles 31(1990), 1571; J. Med. Chem.
  • one object of the present invention is to provide the compound of formula (1) having a good use of antiviral agent, pharmaceutically acceptable salts or isomers thereof.
  • the compound of formula (1) according to the present invention is a type of acyclic nucleoside phosphonate derivative having a natural base, such as for example, adenine, guanine, uracil, cytosine, thymine or derivatives thereof:
  • n denotes an integer of 1 or 2 and Y 1 represents O, CH 2 or N—R (R represents C 1 -C 7 -alkyl or C 6 -C 12 -aryl).
  • the compound of formula (1) according to the present invention may have one or more asymmetric carbon atoms in the structure depending on the kind of substituents, it can be present in the form of the individual enantiomers, diastereomers, or mixtures thereof including racemate. Further, when a double bond is included in the structure, it can be present in the form of E or Z isomer. Thus, the present invention also includes all of these isomers and their mixtures.
  • the compound of formula (1) according to the present invention can form a pharmaceutically acceptable salt.
  • Such salt includes non-toxic acid addition salt containing pharmaceutically acceptable anion, for example a salt with inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, hydriodic acid, etc., a salt with organic carboxylic acids such as tartaric acid, formic acid, citric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, gluconic acid, benzoic acid, lactic acid, fumaric acid, maleic acid, etc., or a salt with sulfonic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, etc., particularly preferably with sulfuric acid, methanesulfonic acid or hydrohalic acid, etc.
  • inorganic acids such as hydroch
  • the preferred compounds are those wherein
  • n denotes an integer of 1 or 2 and Y 1 represents O, CH 2 or N—R (R represents C 1 -C 7 -alkyl), and
  • R 1 , R 3 , R 7 and R 8 independently of one another represent hydrogen
  • R 2 represents hydrogen or methyl
  • R 4 and R 5 independently of one another represent t-butylcarbonyloxymethyl, isopropoxycarbonyloxymethyl or 2,2,2-trifluoroethyl
  • Y represents —O—
  • Q represents
  • X 1 represents hydrogen, hydroxy, ethoxy, 4-methoxyphenylthio or 4-nitrophenylthio, and X 2 represents amino.
  • the compound of formula (1) according to the present invention can be prepared by a process as explained below, and thus, it is another object of the present invention to provide such a preparation process.
  • conditions of the process such as for example, reactants, solvents, bases, amounts of the reactants used, etc. are not restricted to those explained below.
  • the compound of the present invention may also be conveniently prepared by optionally combining the various synthetic ways described in the present specification or known in the arts, and such a combination can be easily performed by one of ordinary skill in the art to which the present invention pertains.
  • the compound of formula (1) of the present invention can be prepared characterized in that
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 7 , R 8 and Y are defined as previously described, and L represents a leaving group, preferably methanesulfonyloxy, p-toluenesulfonyloxy or halogen, is reacted with a compound represented by the following formula (3):
  • R 1 , R 2 , R 3 , R 7 , R 8 , Y and L are defined as previously described, and R 9 and R 10 independently of one another represent optionally substituted alkyl, is reacted with the compound of formula (3) to produce a compound represented by the following formula (10):
  • R 1 , R 2 , R 3 , R 7 , R 8 , Y and Q are defined as previously described, or
  • R 1 , R 2 , R 3 , R 7 , R 8 , Y and Q are defined as previously described, and R 4 ′ and R 5 ′ represent R 4 and R 5 with the exception of hydrogen, respectively, or further the compounds thus obtained are subjected to conventional conversions (see: U.S. Pat. Nos. 6,037,335, 5,935,946, and 5,792,756).
  • the reactions may be carried out in a solvent and in the presence of a base.
  • a solvent one or more selected from a group consisting of dimethylformamide, dichloromethane, tetrahydrofuran, chloroform, 1-methyl-2-pyrrolidinone and dimethylacetamide
  • the base one or more selected from a group consisting of sodium hydride, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, potassium t-butoxide, hydrogen bis(trimethylsilyl)amide, sodium amide, cesium carbonate and potassium bis(trimethylsilyl)amide can be mentioned.
  • the Lewis acid which can be used in the process variant (b) includes trimethylsilylhalide.
  • this compound is subjected to an ether-forming reaction with an alkylhalide in the presence of a base, or is treated with thionyl chloride, oxalyl chloride or phosphorus pentachloride to produce a dichlorophosphonate derivative which is then reacted with a suitable alcohol or amine to give the desired compound.
  • the phosphonate compound of formula (2) used as a starting material in the above process is itself a novel compound. Therefore, it is another object of the present invention to provide the compound of formula (2).
  • the compound of formula (2) wherein Y is O, R 1 is hydrogen, and each of R 2 , R 3 , R 7 and R 8 is hydrogen or alkyl, that is, a compound of the following formula (8), can be prepared characterized in that (i) an ethylglycolate, the alcohol group of which is protected, represented by the following formula (4):
  • P 1 represents an alcohol-protecting group, preferably benzyl(Bn), tetrahydropyranyl(THP), t-butyldiphenylsilyl(TBDPS), or t-butyldimethylsilyl(TBDMS), is reacted with ethyl magnesium bromide[C 2 H 5 MgBr] or the corresponding alkyl magnesium bromide or alkyl magnesium chloride in the presence of titanium tetraisopropoxide[Ti(OiPr) 4 ], (ii) the resulting cyclopropanol represented by the following formula (5):
  • the resulting product may be further separated and purified by usual work-up processes, such as for example, chromatography, recrystallization, etc.
  • the compound of formula (1) of the present invention can be effectively used as an antiviral agent. Therefore, it is another object of the present invention to provide a composition for the treatment of viral diseases, which comprises as an active ingredient the compound of formula (1), pharmaceutically acceptable salt, hydrate, solvate or isomer thereof together with the pharmaceutically acceptable carrier.
  • the active compound according to the present invention When used for clinical purpose, it is preferably administered in an amount ranging generally from 0.1 to 10000 mg, preferably from 0.5 to 100 mg per kg of body weight a day.
  • the total daily dosage may be administered in once or over several times.
  • the specific administration dosage for the patient can be varied with the specific compound used, body weight, sex or hygienic condition of the subject patient, diet, time or method of administration, excretion rate, mixing ratio of the agent, severity of the disease to be treated, etc.
  • the compound of the present invention may be administered in the form of injections or oral preparations.
  • Injections for example, sterilized aqueous or oily suspension for injection, can be prepared according to the known procedure using suitable dispersing agent, wetting agent, or suspending agent.
  • Solvents which can be used for preparing injections include water, Ringer's fluid and isotonic NaCl solution, and also sterilized fixing oil may be conveniently used as the solvent or suspending media. Any non-stimulative fixing oil including mono-, di-glyceride may be used for this purpose. Fatty acid such as oleic acid may also be used for injections.
  • solid preparations for oral administration, capsules, tablets, pills, powders and granules, etc., preferably capsules and tablets can be mentioned. It is also desirable for tablets and pills to be formulated into enteric-coated preparation.
  • the solid preparations may be prepared by mixing the active compound of formula (1) according to the present invention with at least one carrier selected from a group consisting of inactive diluents such as sucrose, lactose, starch, etc., lubricants such as magnesium stearate, disintegrating agent and binding agent.
  • the active compound of formula (1) can be administered in combination with one or more substances selected from the known anti-cancer or antiviral agents.
  • anti-cancer or antiviral agents which can be administered together with the compound of the present invention in such a manner, 5-Fluorouracil, Cisplatin, Doxorubicin, Taxol, Gemcitabine, Lamivudine, etc. can be mentioned.
  • preparations comprising the compound of the present invention are not restricted to those explained above, but may contain any substances useful for the treatment or prevention of cancers or viral diseases.
  • the title compound was prepared as follows. 12 g(35 mmole) of ethyl 2- ⁇ [t-butyl(diphenyl)silyl]oxy ⁇ acetate was dissolved in 200 ml of tetrahydrofuran(THF) and 2.2 ml of titaniumtetraisopropoxide was added thereto. To the mixture was slowly added 29.2 ml of ethylmagnesiumbromide(3.0M in THF), and the reaction solution was stirred for 12 hours at room temperature. 20 ml of saturated ammonium chloride was added to stop the reaction.
  • the compound prepared in Preparation 1 (6.5 g) was dissolved in 10 ml of dimethylformamide(DMF), 32 ml of lithium t-butoxide(1.0M in THF) was added thereto, and the resulting mixture was stirred for 10 minutes. To the mixture was added 7.0 g of diisopropyl bromomethylphosphonate, and then the temperature was raised to 40° C. and the mixture was stirred for 4 hours. Dimethylformamide(DMF) was removed by distillation under reduced pressure, 40 ml of saturated ammonium chloride was added to the residue, which was then extracted with ethyl acetate.
  • the title compound was prepared as follows. 50 g(146 mmole) of ethyl 2- ⁇ [t-butyl(diphenyl)silyl]oxy ⁇ acetate was dissolved in 700 ml of tetrahydrofuran(THF) and 30.0 ml of titaniumtetraisopropoxide was added thereto. To the mixture was slowly added 290 ml of propylmagnesiumchloride(2.0M in THF) at ⁇ 10° C., and the reaction solution was stirred for 12 hours at room temperature. 200 ml of saturated ammonium chloride was added to stop the reaction.
  • the tetrahydrofuran (THF) used as a solvent was removed by distillation under reduced pressure, and the reaction mixture was extracted twice with 2000 ml of n-hexane.
  • the n-hexane extract was distilled under reduced pressure and purified by silica gel column to give 42 g of the title compound.
  • the compound prepared in Preparation 10 (1.5 g) was dissolved in 50 ml of dichloromethane, 0.85 ml of triethylamine and 0.84 g of methanesulfonylchloride were added thereto, and the resulting mixture was stirred for 30 minutes at room temperature. Saturated ammonium chloride was added to stop the reaction. The product was extracted with dichloromethane and the dichloromethane extract was concentrated by distillation under reduced pressure. The residue was used in the next reaction without any purification.
  • the methanesulfonate thus obtained (430 mg) was dissolved in 18 ml of dimethylformamide, and 57.6 mg (60% purity) of sodium hydride and 162 mg of adenine were added thereto.
  • the reaction mixture was refluxed under heating over 4 hours. Saturated ammonium chloride was added to stop the reaction.
  • Diethyl 1,1-cyclopropane dicarboxylate (20 g) was hydrolyzed in 1N NaOH (107 ml) and ethanol (220 ml) for 16 hours, and the ethanol was removed by distillation under reduced pressure. The remaining starting material was removed by using ethyl acetate and the aqueous layer was acidified by 1N HCl. The reaction mixture was extracted with ethyl acetate and distilled under reduced pressure. The residue was purified by silica gel column to give the title compound in a yield of 94%.
  • the carboxylic acid prepared in Preparation 14 (16 g) was dissolved in dichloromethane, 10.8 ml of oxalyl chloride was added dropwise, and 2 drops of dimethylformamide was added. The reaction mixture was stirred at room temperature for 3 hours and distilled under reduced pressure to give ethoxycarbonyl 1,1-cyclopropane carbonylchloride. This compound, not purified, was dissolved in 30 ml of dimethylformamide and the resulting solution was cooled with water-ice. 36 g of NaN 3 was added and the reaction was carried out at room temperature for 3 hours. The reaction solution was extracted with 100 ml of water and 200 ml of diethylether, and the diethylether extract was concentrated to give crude compound which was purified by silica gel column to give an azide compound.
  • the carboxylate prepared in Preparation 15 (13.2 g) was dissolved in diethylether, to which 1.3 g of LiBH 4 dissolved in diethylether was slowly added dropwise.
  • the reaction misture was stirred at room temperature for 16 hours, and 50 ml of methanol and 5 ml of 1N HCl were added dropwise thereto.
  • the reaction mixture was stirred for 2 hours, the precipitate was removed by suction filtration, and the solvent in the filtrate was removed by distillation under reduced pressure.
  • the residue was purified by silica gel column to give benzyl 1-(hydroxymethyl)cyclopropylcarbamate.
  • This compound (9.3 g) was dissolved in dichloromethane, and 4.2 g of imidazole and 13.5 ml of t-butyldiphenylsilylchloride were added in order.
  • the reaction mixture was stirred at room temperature for 4 hours and the solvent was removed by distillation under reduced pressure.
  • the residue was purified by silica gel column to give benzyl 1-( ⁇ [t-butyl(diphenyl)silyl]oxy ⁇ methyl)cyclopropylcarbamate.
  • the carbamate thus obtained (5.5 g) was dissolved in THF, 3.5 ml of methane iodide (MeI) was added dropwise and then 1 g of NaH was added.
  • the reaction mixture was stirred at room temperature for 4 hours and then extracted with 100 ml of diethylether and 100 ml of water.
  • the diethylether extract was concentrated by distillation under reduced pressure and the residue was purified by silica gel column to give the title compound.
  • the carbamate prepared in Preparation 16 (1.0 g) was dissolved in ethanol, 100 mg of 10% Pd/C was added, and the reaction mixture was subjected to a hydrogenation under hydrogen atmosphere. After the reaction was completed, the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column to give 1-( ⁇ [t-butyl(diphenyl)silyl]oxy ⁇ methyl)-N-methylcyclopropaneamine.
  • the methylcyclopropaneamine thus obtained (1.0 g) was dissolved in dichloromethane, to which 1.03 ml of diisopropylethylamine and 1.3 ml of (diisopropyl phosphoryl)methyl trifluoromethansulfonate were added dropwise.
  • the reaction mixture was reacted under stirring at room temperature for 4 hours, and then extracted with 100 ml of diethylether and 100 ml of water.
  • the solvent in the diethylether extract was removed by distillation under reduced pressure and the residue was purified by silica gel column to give the title compound.
  • the compound prepared in Preparation 17 (0.32 g) was dissolved in methanol and 1.5 g of ammonium fluoride was added dropwise. The reaction mixture was reacted under stirring at 60° C. for 24 hours and then the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column to give methylaminediisopropylmethylphosphone 1,1-cyclopropane ethyl alcohol.
  • the compound prepared in Preparation 17 (0.32 g) was dissolved in methanol and 1.5 g of ammonium fluoride was added dropwise. The reaction mixture was reacted under stirring at 60° C. for 24 hours and then the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column to give methylaminediisopropylmethylphosphone 1,1-cyclopropane ethyl alcohol.
  • the compound prepared in Preparation 17 (0.32 g) was dissolved in methanol and 1.5 g of ammonium fluoride was added dropwise. The reaction mixture was reacted under stirring at 60° C. for 24 hours and then the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column to give methylaminediisopropylmethylphosphone 1,1-cyclopropane ethyl alcohol.
  • Lithium aluminum hydride (LAH) 15.3 g was dissolved in 39 g of tetrahydrofuran, and 11.7 g of the carboxylic acid prepared in Preparation 21 was slowly added dropwise at 0° C. The reaction solution was refluxed for 17 hours. The reaction was stopped by adding 10% HCl at room temperature and the mixture was extracted with ethyl acetate. The extract was distilled under reduced pressure and the residue was purified by silica gel column to give 8.2 g of diol compound.
  • LAH Lithium aluminum hydride
  • the compound prepared in Preparation 22 (2 g) was dissolved in 50 ml of dichloromethane, and 1.03 g of N-methylmorpholine N-oxide and 103 mg of tetrapropylammoniumperruthenate (TPAP) were added thereto at room temperature.
  • the reaction mixture was stirred for about 1 hour at room temperature and the reaction was stopped by adding 20 ml of water.
  • the reaction solution was extracted with dichloromethane and the extract was concentrated under reduced pressure to give 2.0 g of aldehyde compound.
  • Tetraethylmethylene diphosphonate (1.7 g) was dissolved in 60 ml of tetrahydrofuran (THF). At ⁇ 78° C., 264 mg of NaH was added, the resulting mixture was stirred for 20 minutes, and then 1.9 g of the aldehyde compound as obtained above was added. The reaction solution was stirred at room temperature for 1 hour, and the reaction was stopped by adding 20 ml of water. The reaction solution was extracted with ethyl acetate and the extract was concentrated under reduced pressure. The residue was purified by silica gel column to give 2.32 g of the title compound.
  • the title compound was prepared as follows. 10 g(29 mmole) of ethyl 2- ⁇ [t-butyl(diphenyl)silyl]oxy ⁇ acetate was dissolved in 100 ml of tetrahydrofuran (THF) and 6.0 ml of titaniumtetraisopropoxide was added thereto. To the mixture was slowly added 37 ml of isobutylmagnesiumbromide(2.0M in THF) at ⁇ 10° C., and the reaction solution was stirred for 12 hours at room temperature. 50 ml of saturated ammonium chloride was added to stop the reaction.
  • THF tetrahydrofuran
  • the tetrahydrofuran (THF) used as a solvent was removed by distillation under reduced pressure, and the reaction mixture was extracted twice with 500 ml of n-hexane.
  • the n-hexane extract was distilled under reduced pressure and purified by silica gel column to give 5.0 g of the title compound.
  • Tetraethylmethylene diphosphonate (2.7 g) was dissolved in 30 ml of tetrahydrofuran (THF) at ⁇ 78 and 4 ml of n-butyllithium was added. The resulting mixture was stirred for 20 minutes, and then 1.0 g of the ketone compound as obtained above was added. The reaction mixture was stirred at room temperature for 1 hour and was stopped by adding 20 ml of water. The reaction mixture was extracted with ethyl acetate and concentrated under reduced pressure. The residue was purified by silica gel column to give 654 mg of the title compound.
  • THF tetrahydrofuran
  • Example 3 The compound prepared in Example 3 (41 mg) was dissolved in 5 ml of 2N hydrochloric acid and heated under reflux for 6 hours. Water was removed by distillation under reduced pressure to give 37 mg(Yield 95%) of the title compound as a white solid.
  • Example 5 The compound prepared in Example 5 was reacted according to the same procedure as Example 2 to give the title compound.
  • 6-Chloroguanine derivative prepared in Preparation 6 (100 mg) was dissolved in 10 ml of ethanol, 32 ml of triethylamine and 53 mg of sodium methoxide were added, and the resulting mixture was refluxed for 4 hours. The reaction was stopped by adding 10 ml of water. The reaction solution was extracted with dichloromethane and distilled under reduced pressure. The residue was purified by silica gel column to give a compound wherein 6-position of guanine was substituted by ethoxy group.
  • Example 5 The compound prepared in Example 5 (100 mg) was dissolved in dimethylformamide (2 ml) and then reacted with chloromethyl 3-methylbutyrate in the presence of triethylamine (3 equivalents) at room temperature for 24 hours. The resulting product was purified by silica gel column to give the title compound in a yield of 41%.
  • Example 5 The compound prepared in Example 5 was reacted with chloromethyl butyrate according to the same procedure as Example 19 at room temperature for 24 hours. The resulting product was purified by silica gel column to give the title compound in a yield of 24%.
  • Example 5 The compound prepared in Example 5 was reacted with chloromethyl isobutyrate according to the same procedure as Example 19 at room temperature for 24 hours. The resulting product was purified by silica gel column to give the title compound in a yield of 21%.
  • Example 5 The compound prepared in Example 5 was reacted with chloromethyl 1-pyrrolidinecarboxylate according to the same procedure as Example 19 at room temperature for 24 hours. The resulting product was purified by silica gel column to give the title compound in a yield of 35%.
  • Example 5 The compound prepared in Example 5 was reacted with chloromethyl 1-piperidinecarboxylate according to the same procedure as Example 19 at room temperature for 24 hours. The resulting product was purified by silica gel column to give the title compound in a yield of 39%.
  • Example 5 The compound prepared in Example 5 was reacted with chloromethyl 4-morpholinecarboxylate according to the same procedure as Example 19 at room temperature for 24 hours. The resulting product was purified by silica gel column to give the title compound in a yield of 40%.
  • 6-Chloroguanine derivative prepared in Preparation 6 (4.86 g) was dissolved in 85 ml of methanol and 1.4 g of triethylamine and 2.9 g of 4-methylthiocresol were added. The reaction mixture was reacted under reflux condition for 24 hours. The reaction was stopped by adding 20 ml of water, and the methanol was removed by distillation under reduced pressure. The reaction mixture was extracted with dichloromethane and purified by silica gel column to give a compound wherein 6-position of guanine was substituted by 4-methylphenylthio group.
  • Example 25 The methylphosphonic acid prepared in Example 25 was reacted according to the same procedure as Example 2 to give the title compound.
  • 6-Chloroguanine derivative prepared in Preparation 6 (4.86 g) was dissolved in 85 ml of methanol and 1.4 g of triethylamine and 2.9 g of 4-methoxythiocresol were added. The reaction mixture was reacted under reflux condition for 24 hours. The reaction was stopped by adding 20 ml of water, and the methanol was removed by distillation under reduced pressure. The reaction mixture was extracted with dichloromethane and purified by silica gel column to give a compound wherein 6-position of guanine was substituted by 4-methoxyphenylthio group.
  • Example 5 The compound prepared in Example 5 (187 mg) was mixed with 6 ml of N-methyl-2-pyrrolidone, and 300 mg of triethylamine and 150 mg of chloromethyl t-butylcarbonate were added. The reaction solution was stirred at room temperature for 4 hours. The reaction was stopped by adding 10 ml of water, and the reaction mixture was extracted with ethyl acetate. The extract was distilled under reduced pressure and purified by silica gel column to give the title compound.
  • Example 5 The compound prepared in Example 5 (100 mg) was mixed with 5 ml of N-methyl-2-pyrrolidone, and 110 mg of triethylamine and 150 mg of chloromethyl isopropylcarbonate were added. The reaction solution was stirred at 50 for 4 hours. The reaction was stopped by adding 10 ml of water, and the reaction mixture was extracted with ethyl acetate. The extract was distilled under reduced pressure and purified by silica gel column to give the title compound.
  • Example 2 To the methylphosphonic acid prepared in Example 1 (150 mg) was added dropwise dichloromethane, 0.73 ml of N,N-diethyltrimethylsilylamine was added dropwise thereto, and the resulting mixture was stirred at room temperature for 2 hours. Oxalyl chloride (0.15 ml) and 2 drops of dimethylformamide were added to the reaction vessel. The mixture was stirred for further 2 hours and the solvent was removed by distillation under reduced pressure. To the residue were added 10 ml of pyridine and 2 ml of trifluoroethanol, which was then reacted under stirring for 16 hours. The solvent was removed by distillation under reduced pressure and the residue was purified by silica gel column to give the title compound.
  • Example 5 The compound prepared in Example 5 was reacted according to the same procedure as Example 47 to give the title compound.
  • Example 25 The compound prepared in Example 25 was reacted according to the same procedure as Example 47 to give the title compound.
  • Example 4 The compound prepared in Example 4 was reacted according to the same procedure as Example 47 to give the title compound.
  • Example 7 The compound prepared in Example 7 was reacted according to the same procedure as Example 47 to give the title compound.
  • the compound of the present invention exhibits a potent pharmacological effect to a hepatitis B cell line, HepG2.2.15, and a transgenic mouse, widely used for development of a therapeutic agent against hepatitis B, when intravenously or orally administered.
  • the experimental procedures and results are described below.
  • HBV Hepatitis B Virus
  • HepG2.2.15 cell (M. A Shells et al., P.N.A.S. 84, 1005(1987)), a hepatocarcinoma cell line producing hepatitis B virus, was cultured in DMEM medium(GIBCO BRL, #430-2200) containing 10% FBS(Fetus bovine serum, GIBCO BRL, #16000-044), 1% ABAM (Antibiotic-Antimycotic, GIBCO BRL, #16000-028) and 400 ⁇ g/ml of geneticin(Sigma, #G-9516) in a T-75 flask under the conditions of 5% CO 2 incubator and 37° C. by dividing in a ratio of 1:3 at an interval of 3 days.
  • the cells were distributed into a 96-well plate in the amount of 4 ⁇ 10 4 /well and then when 80-90% of cell density was achieved, the old medium was changed with 200 ⁇ l of DMEM medium containing 2% FBS, 1% ABAM and 400 ⁇ g/ml of geneticin.
  • the drug solution was sequentially diluted five-fold each time, from 100 M to 0.16 M. In order to minimize an experimental error, each treatment was repeated 2-3 times for the respective drugs.
  • the medium was changed every two days. On 10 days after the treatment with drug, 100 ⁇ l of the medium was collected and the degree of inhibition of viral replication by drugs was determined through quantitative PCR (Polymerase Chain Reaction).
  • MTT Thiazolyl Blue Tetrazolium Broide, Amresco, #0793-5G
  • the degree of inhibition by drugs on the replication of hepatitis B virus was determined using the cell culture solution collected on 10th day after the treatment with the drug.
  • the cell culture solution treated with each drug was diluted ten-fold with distilled water and subjected to a pretreatment to destroy the cells by heating them for 15 minutes at 95° C.
  • the 2001-base position that is conserved in all sub-strain of hepatitis B virus and 2319-base position that is between the core antigen gene and polymerase gene were used as 5′-end and 3′-end primer, respectively.
  • the amount of genomic DNA of hepatitis B virus was quantified, and the inhibitory effect by drugs on the replication of hepatitis B virus was determined on the basis thereof.
  • the cell culture solution of hepatitis B virus that was not treated with drug was sequentially diluted and amplified through the PCR.
  • the amplified DNA was subjected to electrophoresis on 2% agarose gel and stained with ethidium bromide (EtBr) to be analyzed by IS-1000 (Innotech Scientific Corporation) Digital Imaging System. Analysis of the cell culture solution treated with drug was then carried out using the dilution fold in the range where linearity is maintained.
  • the DNA obtained from the group treated with drug was amplified through the same PCR method, subjected to electrophoresis on 2% agarose gel, stained with ethidium bromide, and analyzed by IS-1000.
  • the degree of inhibition by drugs in the viral replication was quantified by calculating the ratio of test group to control group.
  • Table 8 summarizes the inhibitory effect (pharmaceutical activity and toxicity) of the typical compounds of the present invention.
  • the compound according to the present invention exhibits 4 to 10-fold greater activity than the comparative compound PMEA that is on Phase III in clinical trials.
  • the compounds were administered via subcutaneous and oral routes in the following animal test.
  • test compounds were administered to 4-5 weeks old HBV transgenic mice, which were obtained from FVB strain mice according to a method described in a reference (see, Jone D. Morrey, Kevin W. Bailey, Brent E. Korba, Robert W. Sidwell, “Utilization of transgenic mice replicating high levels of hepatitis B virus for antiviral evaluation of lamivudine” Antiviral research, 1999, 42, 97-108), subcutaneously for 9 days in the amount of 10 mg/kg/day and orally for 9 days in the amount of 10, 2 and 0.4 mg/kg/day, once a day, respectively (the same number of males and females were used). Blood was collected from the tail of the mouse and 5 ⁇ l of serum was obtained.
  • HBV DNA was taken from the pretreated solution.
  • the DNA was amplified by the PCR (Polymerase Chain Reaction) in the presence of 4 ⁇ l of 10 ⁇ buffer (Perkin Elmer), 0.8 ⁇ l of 10 mM dNTP, 500 ng of the same HBV primers as used in Experiment 1, 2,125 mM of MgCl 2 , DMSO and Taq polymerase.
  • the amount of HBV DNA was analyzed by electrophoresis in order to evaluate a pharmacological effect of the compound of the present invention. The results are described in the following Table 9.
  • ⁇ mice showing pharmacological effect ⁇ means the mice whose blood does not contain HBV DNA.
  • the compound of the present invention shows a potent hepatitis B therapeutic effect in the tested animals when orally or subcutaneously administered.
  • the compound of the present invention is superior to the comparative compound PMEA, which is on Phase III in clinical trials, it is expected that the compound of the present invention may be used very effectively for the treatment of hepatitis B.

Abstract

The present invention relates to an acyclic nucleoside phosphonate derivative which is useful as an antiviral agent (particularly, against hepatitis B virus), pharmaceutically acceptable salts, stereoisomers, and a process for the preparation thereof.

Description

  • This Application is a Divisional of co-pending application Ser. No. 11/455,679, filed on Jun. 14, 2006, which is a continuation-in-part (CIP) of U.S. application Ser. No. 10/450,780, now U.S. Pat. No. 7,157,448, which application Ser. No. 10/450,780 is the U.S. National Phase of PCT International Application No. PCT/KR2002/00086 filed on Jan. 18, 2002 under 35 U.S.C. §371. Priority is also claimed to Korean Application No. 2001-3087 filed on Jan. 19, 2001 in Korea. The entire contents of each of the above-identified applications are hereby incorporated by reference.
  • TECHNICAL FIELD
  • The present invention relates to an acyclic nucleoside phosphonate derivative represented by the following formula (1):
  • Figure US20100004440A1-20100107-C00001
  • in which
    • Figure US20100004440A1-20100107-P00001
      represents single bond or double bond,
    • R1, R2, R3, R7 and R8 independently of one another represent hydrogen, halogen, hydroxy, amino, C1-C7-alkyl, C2-C6-alkenyl, C1-C5-alkylamino, C1-C5-aminoalkyl, or C1-C5-alkoxy,
    • R4 and R5 independently of one another represent hydrogen, or represent C1-C4-alkyl optionally substituted by one or more substituents selected from the group consisting of halogen (particularly, fluorine), C1-C4-alkoxy, phenoxy, C7-C10-phenylalkoxy and C2-C5-acyloxy, or represent C1-C7-acyl, C6-C12-aryl or optionally substituted carbamoyl, or represent —(CH2)m-OC(═O)-R6 wherein m denotes an integer of 1 to 12 and R6 represents C1-C12-alkyl, C2-C7-alkenyl, C1-C5-alkoxy, C1-C7-alkylamino, di(C1-C7-alkyl)amino, C3-C6-cycloalkyl, or 3 to 6-membered heterocycle having 1 or 2 hetero atoms selected from a group consisting of nitrogen and oxygen,
    • Y represents —O—, —S—, —CH(Z)-, ═C(Z)-, —N(Z)-, ═N—, —SiH(Z)-, or =Si(Z)-, wherein Z represents hydrogen, hydroxy or halogen, or represents C1-C7-alkyl, C1-C5-alkoxy, allyl, hydroxy-C1-C7-alkyl, C1-C7-aminoalkyl or phenyl,
    • Q represents a group having the following formula:
  • Figure US20100004440A1-20100107-C00002
  • wherein
    • X1, X2, X3 and X4 independently of one another represent hydrogen, amino, hydroxy or halogen, or represent C1-C7-alkyl, C1-C5-alkoxy, allyl, hydroxy-C1-C7-alkyl, phenyl or phenoxy each of which is optionally substituted by nitro or C1-C5-alkoxy, or represent C6-C10-arylthio which is optionally substituted by nitro, amino, C1-C6-alkyl or C1-C4-alkoxy, or represent C6-C12-arylamino, C1-C7-alkylamino, di(C1-C7-alkyl)amino, C3-C6-cycloalkylamino or a structure of
  • Figure US20100004440A1-20100107-C00003
  • wherein n denotes an integer of 1 or 2 and Y1 represents O, CH2 or N—R (R represents C1-C7-alkyl or C6-C12-aryl),
    which is useful as an antiviral agent (particularly, against hepatitis B virus), pharmaceutically acceptable salts, stereoisomers, and a process for the preparation thereof.
  • BACKGROUND ART
  • Purine or pyrimidine derivatives have anti-cancer and antiviral activities, and more than 10 kinds of the compounds including AZT, 3TC and ACV have already been commercialized. Particularly, since acyclic nucleoside phosphonate derivatives show a potent antiviral effect, cidopovir has been commercialized as an antiviral agent and many compounds including PMEA and PMPA now entered into the step of clinical trials. However, the earlier developed compounds were not perfect in the aspects of toxicity or pharmaceutical activity, and thus, it is still desired to develop a compound having no toxicity as well as a superior activity. The prior researches for purine or pyrimidine derivatives or acyclic nucleoside phosphonate derivatives as reported heretofore are as follows. Patents: U.S. Pat. No. 5,817,647; U.S. Pat. No. 5,977,061; U.S. Pat. No. 5,886,179; U.S. Pat. No. 5,837,871; U.S. Pat. No. 6,069,249; WO 99/09031; WO96/09307; WO95/22330; U.S. Pat. No. 5,935,946; U.S. Pat. No. 5,877,166; U.S. Pat. No. 5,792,756; Journals: International Journal of Antimicrobial Agents 12 (1999), 81-95; Nature 323 (1986), 464; Heterocycles 31(1990), 1571; J. Med. Chem. 42 (1999), 2064; Pharmacology & Therapeutics 85 (2000), 251; Antiviral Chemistry & Chemotherapy 5 (1994), 57-63.; Bioorganic & Medicinal Chemistry Letters 10 (2000) 2687-2690; Biochemical Pharmacology 60 (2000), 1907-1913; Antiviral Chemistry & Chemotherapy 8 (1997) 557-564; Antimicrobial Agent and Chemotherapy 42 (1999) 2885-2892.
  • DISCLOSURE OF INVENTION
  • Thus, the present inventors extensively studied to develop a compound having a superior biological activity (pharmaceutical effect) to as well as a lower toxicity than the existing acyclic nucleoside phosphonates commercialized or entered into the step of clinical trials. As a result, we found that the above compound of formula (1) characterized by its unique chemical structure exhibits a potent pharmaceutical activity, and then completed the present invention.
  • Therefore, one object of the present invention is to provide the compound of formula (1) having a good use of antiviral agent, pharmaceutically acceptable salts or isomers thereof.
  • It is another object of the present invention to provide a process for the preparation of the compound of formula (1).
  • It is still another object of the present invention to provide intermediates which are advantageously used for the preparation of the compound of formula (1).
  • BEST MODE FOR CARRYING OUT THE INVENTION
  • The compound of formula (1) according to the present invention, as represented below, is a type of acyclic nucleoside phosphonate derivative having a natural base, such as for example, adenine, guanine, uracil, cytosine, thymine or derivatives thereof:
  • Figure US20100004440A1-20100107-C00004
  • in which
    • Figure US20100004440A1-20100107-P00001
      represents single bond or double bond,
    • R1, R2, R3, R7 and R8 independently of one another represent hydrogen, halogen, hydroxy, amino, C1-C7-alkyl, C2-C6-alkenyl, C1-C5-alkylamino, C1-C5-aminoalkyl, or C1-C5-alkoxy,
    • R4 and R5 independently of one another represent hydrogen, or represent C1-C4-alkyl optionally substituted by one or more substituents selected from the group consisting of halogen (particularly, fluorine), C1-C4-alkoxy, phenoxy, C7-C10-phenylalkoxy and C2-C5-acyloxy, or represent C1-C7-acyl, C6-C12-aryl or optionally substituted carbamoyl, or represent —(CH2)m-OC(═O)—R6 wherein m denotes an integer of 1 to 12 and R6 represents C1-C12-alkyl, C2-C7-alkenyl, C1-C5-alkoxy, C1-C7-alkylamino, di(C1-C7-alkyl)amino, C3-C6-cycloalkyl, or 3 to 6-membered heterocycle having 1 or 2 hetero atoms selected from a group consisting of nitrogen and oxygen,
    • Y represents —O—, —S—, —CH(Z)-, ═C(Z)-, —N(Z)-, ═N—, —SiH(Z)-, or =Si(Z)-, wherein Z represents hydrogen, hydroxy or halogen, or represents C1-C7-alkyl, C1-C5-alkoxy, allyl, hydroxy-C1-C7-alkyl, C1-C7-aminoalkyl or phenyl,
    • Q represents a group having the following formula:
  • Figure US20100004440A1-20100107-C00005
  • wherein
    • X1, X2, X3 and X4 independently of one another represent hydrogen, amino, hydroxy or halogen, or represent C1-C7-alkyl, C1-C5-alkoxy, allyl, hydroxy-C1-C7-alkyl, phenyl or phenoxy each of which is optionally substituted by nitro or C1-C5-alkoxy, or represent C6-C10-arylthio which is optionally substituted by nitro, amino, C1-C6-alkyl or C1-C4-alkoxy, or represent C6-C12-arylamino, C1-C7-alkylamino, di(C1-C7-alkyl)amino, C3-C6-cycloalkylamino or a structure of
  • Figure US20100004440A1-20100107-C00006
  • wherein n denotes an integer of 1 or 2 and Y1 represents O, CH2 or N—R (R represents C1-C7-alkyl or C6-C12-aryl).
  • Since the compound of formula (1) according to the present invention may have one or more asymmetric carbon atoms in the structure depending on the kind of substituents, it can be present in the form of the individual enantiomers, diastereomers, or mixtures thereof including racemate. Further, when a double bond is included in the structure, it can be present in the form of E or Z isomer. Thus, the present invention also includes all of these isomers and their mixtures.
  • Also, the compound of formula (1) according to the present invention can form a pharmaceutically acceptable salt. Such salt includes non-toxic acid addition salt containing pharmaceutically acceptable anion, for example a salt with inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, hydriodic acid, etc., a salt with organic carboxylic acids such as tartaric acid, formic acid, citric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, gluconic acid, benzoic acid, lactic acid, fumaric acid, maleic acid, etc., or a salt with sulfonic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, etc., particularly preferably with sulfuric acid, methanesulfonic acid or hydrohalic acid, etc.
  • Among the compound of formula (1) showing a potent pharmaceutical activity, the preferred compounds are those wherein
    • Figure US20100004440A1-20100107-P00001
      represents single bond,
    • R1, R2, R3, R7 and R8 independently of one another represent hydrogen, fluorine, hydroxy, C1-C7-alkyl, C2-C6-alkenyl, C1-C5-alkylamino, C1-C5-aminoalkyl, or C1-C5-alkoxy,
    • R4 and R5 independently of one another represent hydrogen, or represent C1-C4-alkyl optionally substituted by one or more substituents selected from the group consisting of fluorine, C1-C4-alkoxy and phenoxy, or represent carbamoyl substituted by C1-C5-alkyl, or represent —(CH2)m-OC(═O)—R6 wherein m denotes an integer of 1 to 12 and R6 represents C1-C12-alkyl, C2-C7-alkenyl, C1-C5-alkoxy, C1-C7-alkylamino, di(C1-C7-alkyl)amino, C3-C6-cycloalkyl, or 3 to 6-membered heterocycle having 1 or 2 hetero atoms selected from a group consisting of nitrogen and oxygen,
    • Y represents —O—, —S—, or —N(Z)-, wherein Z represents hydrogen, hydroxy, C1-C7-alkyl, or hydroxy-C1-C7-alkyl,
    • Q represents a group having the following formula:
  • Figure US20100004440A1-20100107-C00007
  • wherein
    • X1 represents hydrogen, amino, hydroxy or halogen, or represents C1-C7-alkyl, C1-C5-alkoxy, hydroxy-C1-C7-alkyl or phenoxy each of which is optionally substituted by nitro or C1-C5-alkoxy, or represents C6-C10-arylthio which is optionally substituted by nitro, amino, C1-C6-alkyl or C1-C4-alkoxy, or represents C6-C12-arylamino, C1-C7-alkylamino, di(C1-C7-alkyl)amino, C3-C6-cycloalkylamino or a structure of
  • Figure US20100004440A1-20100107-C00008
  • wherein n denotes an integer of 1 or 2 and Y1 represents O, CH2 or N—R (R represents C1-C7-alkyl), and
    • X2, X3 and X4 independently of one another represent hydrogen, amino, hydroxy, halogen, C1-C7-alkyl, C1-C5-alkoxy, or C1-C7-alkylamino.
  • Most preferred compounds are those wherein
    Figure US20100004440A1-20100107-P00001
    represents single bond, R1, R3, R7 and R8 independently of one another represent hydrogen, R2 represents hydrogen or methyl, R4 and R5 independently of one another represent t-butylcarbonyloxymethyl, isopropoxycarbonyloxymethyl or 2,2,2-trifluoroethyl, Y represents —O—, Q represents
  • Figure US20100004440A1-20100107-C00009
  • wherein X1 represents hydrogen, hydroxy, ethoxy, 4-methoxyphenylthio or 4-nitrophenylthio, and X2 represents amino.
  • Typical examples of the compound of formula (1) according to the present invention are described in the following Tables 1 and 7.
  • TABLE 1
    COM.
    NO. STRUCTURE
    1
    Figure US20100004440A1-20100107-C00010
    2
    Figure US20100004440A1-20100107-C00011
    3
    Figure US20100004440A1-20100107-C00012
    4
    Figure US20100004440A1-20100107-C00013
    5
    Figure US20100004440A1-20100107-C00014
    6
    Figure US20100004440A1-20100107-C00015
    7
    Figure US20100004440A1-20100107-C00016
    8
    Figure US20100004440A1-20100107-C00017
    9
    Figure US20100004440A1-20100107-C00018
    10
    Figure US20100004440A1-20100107-C00019
    11
    Figure US20100004440A1-20100107-C00020
    12
    Figure US20100004440A1-20100107-C00021
    13
    Figure US20100004440A1-20100107-C00022
    14
    Figure US20100004440A1-20100107-C00023
    15
    Figure US20100004440A1-20100107-C00024
    16
    Figure US20100004440A1-20100107-C00025
    17
    Figure US20100004440A1-20100107-C00026
    18
    Figure US20100004440A1-20100107-C00027
    19
    Figure US20100004440A1-20100107-C00028
    20
    Figure US20100004440A1-20100107-C00029
    21
    Figure US20100004440A1-20100107-C00030
    22
    Figure US20100004440A1-20100107-C00031
    23
    Figure US20100004440A1-20100107-C00032
    24
    Figure US20100004440A1-20100107-C00033
    25
    Figure US20100004440A1-20100107-C00034
    26
    Figure US20100004440A1-20100107-C00035
    27
    Figure US20100004440A1-20100107-C00036
    28
    Figure US20100004440A1-20100107-C00037
    29
    Figure US20100004440A1-20100107-C00038
    30
    Figure US20100004440A1-20100107-C00039
    31
    Figure US20100004440A1-20100107-C00040
    32
    Figure US20100004440A1-20100107-C00041
    33
    Figure US20100004440A1-20100107-C00042
    34
    Figure US20100004440A1-20100107-C00043
    35
    Figure US20100004440A1-20100107-C00044
    36
    Figure US20100004440A1-20100107-C00045
    37
    Figure US20100004440A1-20100107-C00046
    38
    Figure US20100004440A1-20100107-C00047
    39
    Figure US20100004440A1-20100107-C00048
    40
    Figure US20100004440A1-20100107-C00049
    41
    Figure US20100004440A1-20100107-C00050
    42
    Figure US20100004440A1-20100107-C00051
    43
    Figure US20100004440A1-20100107-C00052
    44
    Figure US20100004440A1-20100107-C00053
  • TABLE 2
    Figure US20100004440A1-20100107-C00054
    COM. NO. X1 X2 R4 R5
    45 OH NH2 CH2CF3 CH2CF3
    46 Cl NH2 CH2CF3 CH2CF3
    47 NH2 NH2 CH2CF3 CH2CF3
    48 NH2 H CH2CF3 CH2CF3
    49 H NH2 CH2CF3 CH2CF3
    50
    Figure US20100004440A1-20100107-C00055
    NH2 CH2CF3 CH2CF3
    51 NHC2H5 NH2 CH2CF3 CH2CF3
    52 N(CH3)2 NH2 CH2CF3 CH2CF3
    53
    Figure US20100004440A1-20100107-C00056
    NH2 CH2CF3 CH2CF3
    54 OCH3 NH2 CH2CF3 CH2CF3
    55 CH3 NH2 CH2CF3 CH2CF3
    56 C2H5 NH2 CH2CF3 CH2CF3
    57
    Figure US20100004440A1-20100107-C00057
    NH2 CH2CF3 CH2CF3
    58
    Figure US20100004440A1-20100107-C00058
    NH2 CH2CF3 CH2CF3
    59
    Figure US20100004440A1-20100107-C00059
    NH2 CH2CF3 CH2CF3
    60
    Figure US20100004440A1-20100107-C00060
    NH2 CH2CF3 CH2CF3
    61
    Figure US20100004440A1-20100107-C00061
    NH2 CH2CF3 CH2CF3
    62
    Figure US20100004440A1-20100107-C00062
    NH2 CH2CF3 CH2CF3
    63
    Figure US20100004440A1-20100107-C00063
    NH2 CH2CF3 CH2CF3
    64
    Figure US20100004440A1-20100107-C00064
    NH2 CH2CF3 CH2CF3
    65
    Figure US20100004440A1-20100107-C00065
    NH2 H H
    66
    Figure US20100004440A1-20100107-C00066
    NH2 H H
    67
    Figure US20100004440A1-20100107-C00067
    NH2 H H
    68
    Figure US20100004440A1-20100107-C00068
    NH2
    Figure US20100004440A1-20100107-C00069
    Figure US20100004440A1-20100107-C00070
    69 H NH2
    Figure US20100004440A1-20100107-C00071
    Figure US20100004440A1-20100107-C00072
    70 H NH2
    Figure US20100004440A1-20100107-C00073
    Figure US20100004440A1-20100107-C00074
    71 H NH2
    Figure US20100004440A1-20100107-C00075
    Figure US20100004440A1-20100107-C00076
    72 H NH2
    Figure US20100004440A1-20100107-C00077
    Figure US20100004440A1-20100107-C00078
    73 H NH2
    Figure US20100004440A1-20100107-C00079
    Figure US20100004440A1-20100107-C00080
    74 H NH2
    Figure US20100004440A1-20100107-C00081
    Figure US20100004440A1-20100107-C00082
    75 H NH2
    Figure US20100004440A1-20100107-C00083
    Figure US20100004440A1-20100107-C00084
    76 H NH2
    Figure US20100004440A1-20100107-C00085
    Figure US20100004440A1-20100107-C00086
    77 H NH2
    Figure US20100004440A1-20100107-C00087
    Figure US20100004440A1-20100107-C00088
    78 H NH2
    Figure US20100004440A1-20100107-C00089
    Figure US20100004440A1-20100107-C00090
    79
    Figure US20100004440A1-20100107-C00091
    NH2
    Figure US20100004440A1-20100107-C00092
    Figure US20100004440A1-20100107-C00093
    80 H NH2
    Figure US20100004440A1-20100107-C00094
    Figure US20100004440A1-20100107-C00095
    81 H NH2
    Figure US20100004440A1-20100107-C00096
    Figure US20100004440A1-20100107-C00097
    82 H NH2
    Figure US20100004440A1-20100107-C00098
    Figure US20100004440A1-20100107-C00099
    83 OH NH2
    Figure US20100004440A1-20100107-C00100
    Figure US20100004440A1-20100107-C00101
    84 OH NH2
    Figure US20100004440A1-20100107-C00102
    Figure US20100004440A1-20100107-C00103
    85
    Figure US20100004440A1-20100107-C00104
    NH2
    Figure US20100004440A1-20100107-C00105
    Figure US20100004440A1-20100107-C00106
    86 OH NH2
    Figure US20100004440A1-20100107-C00107
    Figure US20100004440A1-20100107-C00108
    87
    Figure US20100004440A1-20100107-C00109
    NH2
    Figure US20100004440A1-20100107-C00110
    Figure US20100004440A1-20100107-C00111
    88
    Figure US20100004440A1-20100107-C00112
    NH2
    Figure US20100004440A1-20100107-C00113
    Figure US20100004440A1-20100107-C00114
    89 NH2 H
    Figure US20100004440A1-20100107-C00115
    Figure US20100004440A1-20100107-C00116
    90 NH2 H
    Figure US20100004440A1-20100107-C00117
    Figure US20100004440A1-20100107-C00118
    91 NH2 H
    Figure US20100004440A1-20100107-C00119
    Figure US20100004440A1-20100107-C00120
    92
    Figure US20100004440A1-20100107-C00121
    NH2
    Figure US20100004440A1-20100107-C00122
    Figure US20100004440A1-20100107-C00123
    93
    Figure US20100004440A1-20100107-C00124
    NH2
    Figure US20100004440A1-20100107-C00125
    Figure US20100004440A1-20100107-C00126
    94 NH2 H H H
    95
    Figure US20100004440A1-20100107-C00127
    NH2 H H
    96
    Figure US20100004440A1-20100107-C00128
    NH2 H H
  • TABLE 3
    Figure US20100004440A1-20100107-C00129
    COM. NO. X1 X2 R4 R5
    97 OH NH2 H H
    98 H NH2 H H
    99
    Figure US20100004440A1-20100107-C00130
    NH2 H H
    100
    Figure US20100004440A1-20100107-C00131
    NH2 H H
    101
    Figure US20100004440A1-20100107-C00132
    NH2 H H
    102 NH2 NH2 H H
    103 NH2 H H H
    104 OH H H H
    105 OH NH2
    Figure US20100004440A1-20100107-C00133
    Figure US20100004440A1-20100107-C00134
    106 H NH2
    Figure US20100004440A1-20100107-C00135
    Figure US20100004440A1-20100107-C00136
    107 NH2 H
    Figure US20100004440A1-20100107-C00137
    Figure US20100004440A1-20100107-C00138
    108
    Figure US20100004440A1-20100107-C00139
    NH2
    Figure US20100004440A1-20100107-C00140
    Figure US20100004440A1-20100107-C00141
    109 OH NH2
    Figure US20100004440A1-20100107-C00142
    Figure US20100004440A1-20100107-C00143
    110 H NH2
    Figure US20100004440A1-20100107-C00144
    Figure US20100004440A1-20100107-C00145
    111 NH2 H
    Figure US20100004440A1-20100107-C00146
    Figure US20100004440A1-20100107-C00147
    112
    Figure US20100004440A1-20100107-C00148
    NH2
    Figure US20100004440A1-20100107-C00149
    Figure US20100004440A1-20100107-C00150
    113
    Figure US20100004440A1-20100107-C00151
    NH2
    Figure US20100004440A1-20100107-C00152
    Figure US20100004440A1-20100107-C00153
    114
    Figure US20100004440A1-20100107-C00154
    NH2 CH2CF3 CH2CF3
    115
    Figure US20100004440A1-20100107-C00155
    NH2 CH2CF3 CH2CF3
    116
    Figure US20100004440A1-20100107-C00156
    NH2
    Figure US20100004440A1-20100107-C00157
    Figure US20100004440A1-20100107-C00158
    117
    Figure US20100004440A1-20100107-C00159
    NH2
    Figure US20100004440A1-20100107-C00160
    Figure US20100004440A1-20100107-C00161
    118
    Figure US20100004440A1-20100107-C00162
    NH2
    Figure US20100004440A1-20100107-C00163
    Figure US20100004440A1-20100107-C00164
  • TABLE 4
    Figure US20100004440A1-20100107-C00165
    COM. NO. Z X1 X2 R4 R5
    119 H OH NH2 H H
    120 H H NH2 H H
    121 H NH2 H H H
    122 CH3 OH NH2 H H
    123 CH3 H NH2 H H
    124 CH3 NH2 H H H
    125 C2H5 NH2 H H H
    126 CH3 NH2 H
    Figure US20100004440A1-20100107-C00166
    Figure US20100004440A1-20100107-C00167
    127 CH3 NH2 H
    Figure US20100004440A1-20100107-C00168
    Figure US20100004440A1-20100107-C00169
    128 C2H5 H NH2
    Figure US20100004440A1-20100107-C00170
    Figure US20100004440A1-20100107-C00171
    129 C2H5 H NH2
    Figure US20100004440A1-20100107-C00172
    Figure US20100004440A1-20100107-C00173
  • TABLE 5
    Figure US20100004440A1-20100107-C00174
    COM. NO. Z X1 X2 R4 R5
    130 H OH NH2 H H
    131 H H NH2 H H
    132 H NH2 H H H
    133 H OH NH2
    Figure US20100004440A1-20100107-C00175
    Figure US20100004440A1-20100107-C00176
    134 H NH2 H
    Figure US20100004440A1-20100107-C00177
    Figure US20100004440A1-20100107-C00178
    135 CH3 OH NH2 H H
    136 CH3 H NH2 H H
    137 CH3 NH2 H H H
  • TABLE 6
    Figure US20100004440A1-20100107-C00179
    COM. NO. Z X1 X2 R4 R5
    138 H OH NH2 H H
    139 H H NH2 H H
    140 H NH2 H H H
    141 H
    Figure US20100004440A1-20100107-C00180
    NH2 H H
    142 CH3 OH NH2 H H
    143 CH3 NH2 H H H
    144 CH3 H NH2 H H
    145 CH3 NH2 H
    Figure US20100004440A1-20100107-C00181
    Figure US20100004440A1-20100107-C00182
  • TABLE 7
    Figure US20100004440A1-20100107-C00183
    COM. NO. X1 X2 R4 R5
    146 OH NH2 H H
    147 H NH2 H H
    148 NH2 H H H
    149 OH NH2
    Figure US20100004440A1-20100107-C00184
    Figure US20100004440A1-20100107-C00185
    150 H NH2
    Figure US20100004440A1-20100107-C00186
    Figure US20100004440A1-20100107-C00187
    151 NH2 H
    Figure US20100004440A1-20100107-C00188
    Figure US20100004440A1-20100107-C00189
    152 NH2 H
    Figure US20100004440A1-20100107-C00190
    Figure US20100004440A1-20100107-C00191
    153 OH NH2
    Figure US20100004440A1-20100107-C00192
    Figure US20100004440A1-20100107-C00193
  • More particularly preferable compounds among the compounds described in the above Tables 1 and 7 are as follows:
  • ({1-[(6-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methylphosphonic acid (Compound 1);
  • 3-[({1-[(6-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate(Compound 2);
  • ({1-[(2-amino-6-chloro-9H-purin-9-yl)methyl]cyclopropyl}oxy)methylphosphonic acid(Compound 3);
  • 3-[({1-[(2-amino-6-chloro-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate(Compound 4);
  • ({1-[(2-amino-6-hydroxy-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl phosphonic acid(Compound 5);
  • 3-[({1-[(2-amino-6-hydroxy-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-8,8-d imethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate(Compound 6);
  • ({1-[(2-amino-6-fluoro-9H-purin-9-yl)methyl]cyclopropyl}oxy)methylphosphonic acid(Compound 7);
  • 3-[({1-[(2-amino-6-fluoro-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate(Compound 8);
  • ({1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methylphosphonic acid (Compound 9);
  • 3-[({1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate(Compound 10);
  • ({1[(2-amino-6-cyclopropylamino-9H-purin-9-yl)methyl]cyclopropyl}oxy)meth-ylphosphonic acid(Compound 11);
  • 3-[({1-[(2-amino-6-cyclopropylamino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate(Compound 12);
  • [(1-{[2-amino-6-(dimethylamino)-9H-purin-9-yl]methyl}cyclopropyl)oxy]methylp hosphonic acid(Compound 15);
  • 3-{[(1-{[2-amino-6-(dimethylamino)-9H-purin-9-yl]methyl}cyclopropyl)oxy]methyl}-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate(Compound 16);
  • [(1-{[2-amino-6-(isopropylamino)-9H-purin-9-yl]methyl}cyclopropyl)oxy]methyl phosphonic acid(Compound 17);
  • 3-{[(1-{[2-amino-6-(isopropylamino)-9H-purin-9-yl]methyl}cyclopropyl)oxy]methyl}-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate(Compound 18);
  • ({1-[(2,6-diamino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methylphosphonic acid(Compound 19);
  • 3-[({1-[(2,6-diamino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate(Compound 20);
  • ({1-[(2-amino-6-methoxy-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl phosphonic acid (Compound 21);
  • 3-[({1-[(2-amino-6-methoxy-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate(Compound 22);
  • ({1-[(2-amino-6-ethoxy-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl phosphonic acid (Compound 23);
  • 3-[({1-[(2-amino-6-ethoxy-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate(Compound 24);
  • ({1-[(2-amino-6-methyl-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl phosphonic acid(Compound 25);
  • 3-[({1-[(2-amino-6-methyl-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate(Compound 26);
  • [(1-{[5-methyl-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl]methyl}cyclopropyl)oxy]methylphosphonic acid(Compound 31);
  • 8,8-dimethyl-3-{[(1-{[5-methyl-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl]methyl}cyclopropyl)oxy]methyl}-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate (Compound 32);
  • [(1-{[2-amino-6-(4-morpholinyl)-9H-purin-9-yl]methyl}cyclopropyl)oxy]methyl phosphonic acid(Compound 37);
  • 3-{[(1-{[2-amino-6-(4-morpholinyl)-9H-purin-9-yl]methyl}cyclopropyl)oxy]met-hyl}-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate(Compound 38);
  • bis(2,2,2-trifluoroethyl)({1-[(2-amino-6-hydroxy-9H-purin-9-yl)methyl]cyclopropyl}oxy)methylphosphonate (Compound 45);
  • bis(2,2,2-trifluoroethyl)({1-[(2-amino-6-chloro-9H-purin-9-yl)methyl]cyclopropyl}oxy)methylphosphonate(Compound 46);
  • bis(2,2,2-trifluoroethyl)({1-[(2,6-diamino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methylphosphonate(Compound 47);
  • bis(2,2,2-trifluoroethyl)({1-[(6-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methylphosphonate(Compound 48);
  • bis(2,2,2-trifluoroethyl)({1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methylphosphonate(Compound 49);
  • bis(2,2,2-trifluoroethyl)({1-[(2-amino-6-dimethylamino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methylphosphonate(Compound 52);
  • bis(2,2,2-trifluoroethyl)({1-[(2-amino-6-isopropylamino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methylphosphonate(Compound 53);
  • bis(2,2,2-trifluoroethyl)({1-[(2-amino-6-methoxy-9H-purin-9-yl)methyl]cyclopropyl}oxy)methylphosphonate(Compound 54);
  • bis(2,2,2-trifluoroethyl)[(1-{[2-amino-6-(4-morpholinyl)-9H-purin-9-yl]methyl}cyclopropyl)oxy]methylphosphonate(Compound 58);
  • bis(2,2,2-trifluoroethyl)[(1-{[2-amino-6-(phenylsulfanyl)-9H-purin-9-yl]methyl}cyclopropyl)oxy]methylphosphonate(Compound 61);
  • bis(2,2,2-trifluoroethyl){[1-({2-amino-6-[(4-methylphenyl)sulfanyl]-9H-purin-9-yl}methyl)cyclopropyl]oxy}methylphosphonate(Compound 62);
  • bis(2,2,2-trifluoroethyl){[1-({2-amino-6-[(4-methoxyphenyl)sulfanyl]-9H-purin-9-yl}methyl)cyclopropyl]oxy}methylphosphonate(Compound 63);
  • bis(2,2,2-trifluoroethyl){[1-({2-amino-6-[(4-nitrophenyl)sulfanyl]-9H-purin-9-yl}methyl)cyclopropyl]oxy}methylphosphonate(Compound 64);
  • [(1-{[2-amino-6-(phenylsulfanyl)-9H-purin-9-yl]methyl}cyclopropyl)oxy]methyl phosphonic acid(Compound 65);
  • {[1-({2-amino-6-[(4-methylphenyl)sulfanyl]-9H-purin-9-yl}methyl)cyclopropyl]oxy}methylphosphonic acid(Compound 66);
  • 3-({[1-({2-amino-6-[(4-methylphenyl)sulfanyl]-9H-purin-9-yl}methyl)cyclo propyl]oxy}methyl)-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate (Compound 68);
  • bis{[(t-butoxycarbonyl)oxy]methyl}({1-[(2-amino-9H-purin-9-yl)methyl]cyclo propyl}oxy)methylphosphonate(Compound 69);
  • bis{[(isopropoxycarbonyl)oxy]methyl}({1-[(2-amino-9H-purin-9-yl)methyl]cyclo propyl}oxy)methylphosphonate (Compound 70);
  • bis{[(ethoxycarbonyl)oxy]methyl}({1-[(2-amino-9H-purin-9-yl)methyl]cyclo propyl}oxy)methylphosphonate (Compound 71);
  • bis{[(isobutoxycarbonyl)oxy]methyl}({1-[(2-amino-9H-purin-9-yl)methyl]cyclo propyl}oxy)methylphosphonate (Compound 72);
  • 3-[({1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-9-methyl-3,7-dioxo-2,4,6-trioxa-385-phosphadec-1-yl 3-methylbutanoate(Compound 74);
  • 3-[({1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-8-methyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl 2-methylpropanoate(Compound 78);
  • 3-({[1-({2-amino-6-[(4-methoxyphenyl)sulfanyl]-9H-purin-9-yl}methyl)cyclo propyl]oxy}methyl)-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate (Compound 79);
  • 3-[({1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-3,7-dioxo-7-(1-pyrrolidinyl)-2,4,6-trioxa-385-phosphahept-1-yl 1-pyrrolidinecarboxylate(Compound 80);
  • 3-[({1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-3,7-dioxo-7-(1-piperidinyl)-2,4,6-trioxa-385-phosphahept-1-yl 1-piperidinecarboxylate(Compound 81);
  • 3-[({1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-7-(4-morpholinyl)-3,7-dioxo-2,4,6-trioxa-385-phosphahept-1-yl 4-morpholinecarboxylate(Compound 82);
  • bis{[(t-butoxycarbonyl)oxy]methyl}[(1-{[2-amino-6-hydroxy-9H-purin-9-yl]methyl}cyclopropyl)oxy]methylphosphonate(Compound 83);
  • bis{[(isopropoxycarbonyl)oxy]methyl}[(1-{[2-amino-6-hydroxy-9H-purin-9-yl]methyl}cyclopropyl)oxy]methylphosphonate(Compound 84);
  • bis{[(isopropoxycarbonyl)oxy]methyl}{[1-({2-amino-[6-(4-methoxyphenyl)sulfanyl]-9H-purin-9-yl}methyl)cyclopropyl]oxy}methylphosphonate(Compound 85);
  • 3-[({1-[(2-amino-6-hydroxy-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-7-cyclopentyl-3,7-dioxo-2,4,6-trioxa-385-phosphahept-1-yl cyclopentanecarboxylate (Compound 86);
  • 3-({[1-({2-amino-[6-(4-nitrophenyl)sulfanyl]-9H-purin-9-yl}methyl)cyclopropyl]oxy}methyl)-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate (Compound 87);
  • bis{[(isopropoxycarbonyl)oxy]methyl}{[1-({2-amino-[6-(4-nitrophenyl)sulfanyl]-9H-purin-9-yl}methyl)cyclopropyl]oxy}methylphosphonate(Compound 88);
  • bis{[(isopropoxycarbonyl)oxy]methyl}({1-[(6-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methylphosphonate(Compound 89);
  • 3-[({1-[(6-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-9-methyl-3,7-dioxo-2,4,6-trioxa-385-phosphadec-1-yl 3-methylbutanoate(Compound 90);
  • 3-[({1-[(6-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-7-cyclopentyl-3,7-dioxo-2,4,6-trioxa-385-phosphahept-1-yl cyclopentanecarboxylate(Compound 91);
  • bis{[(t-butoxycarbonyl)oxy]methyl}{[1-({2-amino-[6-(4-methoxyphenyl)sulfanyl]-9H-purin-9-yl}methyl)cyclopropyl]oxy}methylphosphonate(Compound 92);
  • bis{[(t-butoxycarbonyl)oxy]methyl}{[1-({2-amino-[6-(4-nitrophenyl)sulfanyl]-9H-purin-9-yl}methyl)cyclopropyl]oxy}methylphosphonate(Compound 93);
  • {[1-({2-amino-[6-(4-nitrophenyl)sulfanyl]-9H-purin-9-yl}methyl)cyclopropyl]oxy}methylphosphonic acid(Compound 95);
  • {[1-({2-amino-[6-(4-methoxyphenyl)sulfanyl]-9H-purin-9-yl}methyl)cyclopropyl]oxy}methylphosphonic acid(Compound 96);
  • ({1-[(2-amino-6-hydroxy-9H-purin-9-yl)methyl]-2-methylcyclopropyl}oxy)methylphosphonic acid(Compound 97);
  • ({1-[(2-amino-9H-purin-9-yl)methyl]-2-methylcyclopropyl}oxy)methylphosphonic acid(Compound 98);
  • {[1-({2-amino-[6-(4-methoxyphenyl)sulfanyl]-9H-purin-9-yl}methyl)-2-methyl cyclopropyl]oxy}methylphosphonic acid(Compound 99);
  • {[1-({2-amino-[6-(4-nitrophenyl)sulfanyl]-9H-purin-9-yl}methyl)-2-methylcyclopropyl]oxy}methylphosphonic acid(Compound 100);
  • {[1-({2-amino-[6-(4-methylphenyl)sulfanyl]-9H-purin-9-yl}methyl)-2-methyl cyclopropyl]oxy}methylphosphonic acid(Compound 101);
  • ({1-[(2,6-diamino-9H-purin-9-yl)methyl]-2-methylcyclopropyl}oxy)methyl phosphonic acid(Compound 102);
  • ({1-[(6-amino-9H-purin-9-yl)methyl]-2-methylcyclopropyl}oxy)methylphosphonic acid(Compound 103);
  • 3-[({1-[(2-amino-6-hydroxy-9H-purin-9-yl)methyl]-2-methylcyclopropyl}oxy)methyl]-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate(Compound 105);
  • 3-[({1-[(2-amino-9H-purin-9-yl)methyl]-2-methylcyclopropyl}oxy)methyl]-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate(Compound 106);
  • 3-[({1-[(6-amino-9H-purin-9-yl)methyl]-2-methylcyclopropyl}oxy)methyl]-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate(Compound 107);
  • 3-({[1-({2-amino-6-[(4-methoxyphenyl)sulfanyl]-9H-purin-9-yl}methyl)-2-methyl cyclopropyl]oxy}methyl)-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate (Compound 108);
  • bis{[(isopropoxycarbonyl)oxy]methyl}[(1-{[2-amino-6-hydroxy-9H-purin-9-yl]methyl}-2-methylcyclopropyl)oxy]methylphosphonate(Compound 109);
  • bis{[(isopropoxycarbonyl)oxy]methyl}({1-[(2-amino-9H-purin-9-yl)methyl]-2-methylcyclopropyl}oxy)methylphosphonate(Compound 110);
  • bis{[(isopropoxycarbonyl)oxy]methyl}{[1-({2-amino-[6-(4-methoxyphenyl)sulfanyl]-9H-purin-9-yl}methyl)-2-methylcyclopropyl]oxy}methylphosphonate (Compound 112);
  • bis{[(t-butoxycarbonyl)oxy]methyl}{[1-({2-amino-[6-(4-methoxyphenyl)sulfanyl]-9H-purin-9-yl}methyl)-2-methylcyclopropyl]oxy}methylphosphonate(Compound 113);
  • bis(2,2,2-trifluoroethyl){[1-({2-amino-6-[(4-methoxyphenyl)sulfanyl]-9H-purin-9-yl}methyl)-2-methylcyclopropyl]oxy}methylphosphonate(Compound 114);
  • bis(2,2,2-trifluoroethyl){[1-({2-amino-6-[(4-nitrophenyl)sulfanyl]-9H-purin-9-yl}methyl)-2-methylcyclopropyl]oxy}methylphosphonate(Compound 115);
  • bis{[(t-butoxycarbonyl)oxy]methyl}{[1-({2-amino-[6-(4-nitrophenyl)sulfanyl]-9H-purin-9-yl}methyl)-2-methylcyclopropyl]oxy}methylphosphonate(Compound 116);
  • bis{[(isopropoxycarbonyl)oxy]methyl}{[1-({2-amino-[6-(4-nitrophenyl)sulfanyl]-9H-purin-9-yl}methyl)-2-methylcyclopropyl]oxy}methylphosphonate(Compound 117);
  • 3-({[1-({2-amino-6-[(4-nitrophenyl)sulfanyl]-9H-purin-9-yl}methyl)-2-methyl cyclopropyl]oxy}methyl)-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate (Compound 118);
  • ({1-[(2-amino-6-hydroxy-9H-purin-9-yl)methyl]cyclopropyl}amino)methyl phosphonic acid(Compound 119);
  • ({1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}amino)methylphosphonic acid(Compound 120);
  • ({1-[(6-amino-9H-purin-9-yl)methyl]cyclopropyl}amino)methylphosphonic acid(Compound 121);
  • [{1-[(2-amino-6-hydroxy-9H-purin-9-yl)methyl]cyclopropyl}(methyl)amino]methylphosphonic acid(Compound 122);
  • [{1-[(6-amino-9H-purin-9-yl)methyl]cyclopropyl}(ethyl)amino]methylphosphonic acid(Compound 125);
  • 3-{[{(1-[(6-amino-9H-purin-9-yl)methyl]cyclopropyl)(methyl)amino)methyl)-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate(Compound 126);
  • bis{[(isopropoxycarbonyl)oxy]methyl}[{1-[(6-amino-9H-purin-9-yl)methyl]cyclo propyl}(methyl)amino]methylphosphonate(Compound 127);
  • 3-{[{1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}(ethyl)amino]methyl}-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate(Compound 129);
  • (E)-2-{1-[(2-amino-6-hydroxy-9H-purin-9-yl)methyl]cyclopropyl}ethenyl phosphonic acid(Compound 130);
  • (E)-2-{1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}ethenylphosphonic acid (Compound 131);
  • (E)-2-{1-[(6-amino-9H-purin-9-yl)methyl]cyclopropyl}ethenylphosphonic acid (Compound 132);
  • 3-((E)-2-{1-[(2-amino-6-hydroxy-9H-purin-9-yl)methyl]cyclopropyl}ethenyl)-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate(Compound 133);
  • 3-((E)-2-{1-[(6-amino-9H-purin-9-yl)methyl]cyclopropyl}ethenyl)-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate(Compound 134);
  • (E)-2-{1-[(6-amino-9H-purin-9-yl)methyl]cyclopropyl}-1-propenylphosphonic acid(Compound 137);
  • 2-{1-[(2-amino-6-hydroxy-9H-purin-9-yl)methyl]cyclopropyl}ethylphosphonic acid(Compound 138);
  • 2-{1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}ethylphosphonic acid (Compound 139);
  • 2-{1-[(6-amino-9H-purin-9-yl)methyl]cyclopropyl}ethylphosphonic acid (Compound 140);
  • 2-[1-({2-amino-6-[(4-methylphenyl)sulfanyl]-9H-purin-9-yl}methyl)cyclopropyl]ethylphosphonic acid(Compound 141);
  • 2-{1-[(2-amino-6-hydroxy-9H-purin-9-yl)methyl]cyclopropyl}propylphosphonic acid(Compound 142);
  • 2-{1-[(6-amino-9H-purin-9-yl)methyl]cyclopropyl}propylphosphonic acid (Compound 143);
  • 2-{1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}propylphosphonic acid (Compound 144);
  • 3-(2-{1-[(6-amino-9H-purin-9-yl)methyl]cyclopropyl}propyl)-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate(Compound 145);
  • ({1-[(2-amino-6-hydroxy-9H-purin-9-yl)methyl]-2,2-dimethylcyclopropyl}oxy)methylphosphonic acid(Compound 146);
  • ({1-[(2-amino-9H-purin-9-yl)methyl]-2,2-dimethylcyclopropyl}oxy)methyl phosphonic acid(Compound 147);
  • ({1-[(6-amino-9H-purin-9-yl)methyl]-2,2-dimethylcyclopropyl}oxy)methyl phosphonic acid(Compound 148);
  • 3-[({1-[(2-amino-6-hydroxy-9H-purin-9-yl)methyl]-2,2-dimethylcyclopropyl}oxy)methyl]-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate(Compound 149);
  • 3-[({1-[(2-amino-9H-purin-9-yl)methyl]-2,2-dimethylcyclopropyl}oxy)methyl]-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate(Compound 150);
  • 3-[({1-[(6-amino-9H-purin-9-yl)methyl]-2,2-dimethylcyclopropyl}oxy)methyl]-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate(Compound 151);
  • bis{[(isopropoxycarbonyl)oxy]methyl}({1-[(6-amino-9H-purin-9-yl)methyl]-2,2-dimethylcyclopropyl}oxy)methylphosphonate(Compound 152); and
  • bis{[(isopropoxycarbonyl)oxy]methyl}[(1-{[2-amino-6-hydroxy-9H-purin-9-yl]methyl}-2,2-dimethylcyclopropyl)oxy]methylphosphonate(Compound 153).
  • The compound of formula (1) according to the present invention can be prepared by a process as explained below, and thus, it is another object of the present invention to provide such a preparation process. However, conditions of the process, such as for example, reactants, solvents, bases, amounts of the reactants used, etc. are not restricted to those explained below. The compound of the present invention may also be conveniently prepared by optionally combining the various synthetic ways described in the present specification or known in the arts, and such a combination can be easily performed by one of ordinary skill in the art to which the present invention pertains.
  • The compound of formula (1) of the present invention can be prepared characterized in that
  • (a) a compound represented by the following formula (2):
  • Figure US20100004440A1-20100107-C00194
  • in which R1, R2, R3, R4, R5, R7, R8 and Y are defined as previously described, and L represents a leaving group, preferably methanesulfonyloxy, p-toluenesulfonyloxy or halogen, is reacted with a compound represented by the following formula (3):

  • QH   (3)
  • in which Q is defined as previously described, to produce the compound of formula (1),
  • (b) a compound represented by the following formula (9):
  • Figure US20100004440A1-20100107-C00195
  • in which R1, R2, R3, R7, R8, Y and L are defined as previously described, and R9 and R10 independently of one another represent optionally substituted alkyl, is reacted with the compound of formula (3) to produce a compound represented by the following formula (10):
  • Figure US20100004440A1-20100107-C00196
  • in which R1, R2, R3, R7, R8, Y, Q, R9 and R10 are defined as previously described, and the resulting compound of formula (10) is hydrolyzed in the presence of a Lewis acid to produce a compound represented by the following formula (1a):
  • Figure US20100004440A1-20100107-C00197
  • in which R1, R2, R3, R7, R8, Y and Q are defined as previously described, or
  • (c) groups R4′ and R5′ are introduced into the compound of formula (1a) to produce a compound represented by the following formula (1b):
  • Figure US20100004440A1-20100107-C00198
  • in which R1, R2, R3, R7, R8, Y and Q are defined as previously described, and R4′ and R5′ represent R4 and R5 with the exception of hydrogen, respectively, or further the compounds thus obtained are subjected to conventional conversions (see: U.S. Pat. Nos. 6,037,335, 5,935,946, and 5,792,756).
  • In the above process variants (a) to (c) for preparing the compound of formula (1), the reactions may be carried out in a solvent and in the presence of a base. As the solvent, one or more selected from a group consisting of dimethylformamide, dichloromethane, tetrahydrofuran, chloroform, 1-methyl-2-pyrrolidinone and dimethylacetamide can be mentioned, and as the base one or more selected from a group consisting of sodium hydride, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, potassium t-butoxide, hydrogen bis(trimethylsilyl)amide, sodium amide, cesium carbonate and potassium bis(trimethylsilyl)amide can be mentioned. The Lewis acid which can be used in the process variant (b) includes trimethylsilylhalide. Further, in the process variant (c) for introducing the groups R4′ and R 5′ into the compound of formula (1a), this compound is subjected to an ether-forming reaction with an alkylhalide in the presence of a base, or is treated with thionyl chloride, oxalyl chloride or phosphorus pentachloride to produce a dichlorophosphonate derivative which is then reacted with a suitable alcohol or amine to give the desired compound.
  • The phosphonate compound of formula (2) used as a starting material in the above process is itself a novel compound. Therefore, it is another object of the present invention to provide the compound of formula (2).
  • The compound of formula (2) wherein Y is O, R1 is hydrogen, and each of R2, R3, R7 and R8 is hydrogen or alkyl, that is, a compound of the following formula (8), can be prepared characterized in that (i) an ethylglycolate, the alcohol group of which is protected, represented by the following formula (4):
  • Figure US20100004440A1-20100107-C00199
  • in which P1 represents an alcohol-protecting group, preferably benzyl(Bn), tetrahydropyranyl(THP), t-butyldiphenylsilyl(TBDPS), or t-butyldimethylsilyl(TBDMS), is reacted with ethyl magnesium bromide[C2H5MgBr] or the corresponding alkyl magnesium bromide or alkyl magnesium chloride in the presence of titanium tetraisopropoxide[Ti(OiPr)4], (ii) the resulting cyclopropanol represented by the following formula (5):
  • Figure US20100004440A1-20100107-C00200
  • in which P1 is defined as previously described and each of R2′, R3′, R7′ and R8′ represents hydrogen or alkyl, is subjected to an ether-forming reaction in the presence of a base with a compound represented by the following formula (6):
  • Figure US20100004440A1-20100107-C00201
  • in which L, R4 and R5 are defined as previously described, to produce a phosphonate compound represented by the following formula (7):
  • Figure US20100004440A1-20100107-C00202
  • in which P1, R2′, R3′, R7′, R8′, R4 and R5 are defined as previously described, and (iii) the alcohol-protecting group of the resulting compound of formula (7) is removed and a leaving group (L) is introduced to produce a compound represented by the following formula (8):
  • Figure US20100004440A1-20100107-C00203
  • in which L, R2′, R3′, R7′, R8′, R4 and R5 are defined as previously described.
  • The process for preparing the simplest compound of formula (8) (that is, all of R2′, R3′, R7′ and R8′ are hydrogen) is briefly depicted in the following Reaction Scheme 1:
  • Figure US20100004440A1-20100107-C00204
  • The specific reaction conditions of the above process can be referred to the following Preparations and Examples.
  • Further, the compound of formula (2) wherein Y is —CH2—, and each of R1, R2, R3, R7 and R8 is hydrogen, that is a compound of the following formula (11):
  • Figure US20100004440A1-20100107-C00205
  • in which L, R4 and R5 are defined as previously described, can be prepared by a process as depictd in the following Reaction Scheme 2:
  • Figure US20100004440A1-20100107-C00206
  • Reaction Scheme 2 is briefly explained below. (i) According to a known method (see: JOC, 1975, Vol.40, 2969-2970), dialkylmalonate is reacted with dihaloethane to give malonic acid wherein cyclopropyl group is introduced into its 2-position. (ii) The malonic acid is reduced to give diol compound, one hydroxy group of which is then protected with a suitable protecting group (P1 is defined as previously described). Then, the other hydroxy group is oxidized to an aldehyde group. (iii) The resulting aldehyde compound is reacted with tetraalkylmethylenediphosphonate to give the desired phosphonate compound. (iv) The phosphonate compound thus obtained is reduced to give a compound having no unsaturated bond, alcohol-protecting group (P1) is removed, and a leaving group (L) is introduced to give the compound of formula (11).
  • Further, the compound of formula (2) wherein Y is —N(CH3)— and each of R1, R2, R3, R7 and R8 is hydrogen, that is a compound of the following formula (12):
  • Figure US20100004440A1-20100107-C00207
  • in which L, R4 and R5 are defined as previously described, can be prepared by a process as depictd in the following Reaction Scheme 3:
  • Figure US20100004440A1-20100107-C00208
  • Reaction Scheme 3 is briefly explained below. (i) Diethyl 1,1-cyclopropyl dicarboxylate is selectively hydrolyzed to give a monocarboxylic acid. (ii) An amine group is introduced into the monocarboxylic acid according to the known Curtious Reaction (see: S. Linke, G. T. Tisue and W. Lowowski, J. Am. Chem. Soc. 1967, 89, 6308). (iii) The amine group is protected with a suitable protecting group [P2 may be carbamate or various benzyl protecting groups, or alkyl group (methyl, ethyl, etc.)]. (iv) The opposite ester group is reduced into a hydroxy group, which is then protected (P1 is defined as previously described). (v) The compound protected with protecting groups is reacted with methyl iodide in the presence of sodium hydride to introduce methyl group into the amine group. (vi) The amine-protecting group is removed and the resulting compound is reacted with dialkylbromomethylphosphonate to give the desired phosphonate compound. (vii) The alcohol-protecting group (P1) is removed from the phosphonate compound thus obtained and then a leaving group (L) is introduced to give the compound of formula (12).
  • The specific reaction conditions of the above processes can be referred to the following Preparations and Examples.
  • After the reaction is completed, the resulting product may be further separated and purified by usual work-up processes, such as for example, chromatography, recrystallization, etc.
  • The compound of formula (1) of the present invention can be effectively used as an antiviral agent. Therefore, it is another object of the present invention to provide a composition for the treatment of viral diseases, which comprises as an active ingredient the compound of formula (1), pharmaceutically acceptable salt, hydrate, solvate or isomer thereof together with the pharmaceutically acceptable carrier.
  • When the active compound according to the present invention is used for clinical purpose, it is preferably administered in an amount ranging generally from 0.1 to 10000 mg, preferably from 0.5 to 100 mg per kg of body weight a day. The total daily dosage may be administered in once or over several times. However, the specific administration dosage for the patient can be varied with the specific compound used, body weight, sex or hygienic condition of the subject patient, diet, time or method of administration, excretion rate, mixing ratio of the agent, severity of the disease to be treated, etc.
  • The compound of the present invention may be administered in the form of injections or oral preparations.
  • Injections, for example, sterilized aqueous or oily suspension for injection, can be prepared according to the known procedure using suitable dispersing agent, wetting agent, or suspending agent. Solvents which can be used for preparing injections include water, Ringer's fluid and isotonic NaCl solution, and also sterilized fixing oil may be conveniently used as the solvent or suspending media. Any non-stimulative fixing oil including mono-, di-glyceride may be used for this purpose. Fatty acid such as oleic acid may also be used for injections.
  • As the solid preparation for oral administration, capsules, tablets, pills, powders and granules, etc., preferably capsules and tablets can be mentioned. It is also desirable for tablets and pills to be formulated into enteric-coated preparation. The solid preparations may be prepared by mixing the active compound of formula (1) according to the present invention with at least one carrier selected from a group consisting of inactive diluents such as sucrose, lactose, starch, etc., lubricants such as magnesium stearate, disintegrating agent and binding agent.
  • When the compound according to the present invention is clinically applied for obtaining the desired antiviral effect, the active compound of formula (1) can be administered in combination with one or more substances selected from the known anti-cancer or antiviral agents. As the anti-cancer or antiviral agents which can be administered together with the compound of the present invention in such a manner, 5-Fluorouracil, Cisplatin, Doxorubicin, Taxol, Gemcitabine, Lamivudine, etc. can be mentioned.
  • However, preparations comprising the compound of the present invention are not restricted to those explained above, but may contain any substances useful for the treatment or prevention of cancers or viral diseases.
  • The present invention will be more specifically explained in the following Examples and Experiments. However, it should be understood that these Examples and Experiments are intended to illustrate the present invention but not in any manner to limit the scope of the present invention.
  • Preparation 1
  • Synthesis of 1-({[t-butyl(diphenyl)silyl]oxy}methyl)cyclopropanol
  • According to the description in a reference (see: Syn. Lett. 07, 1053-1054, 1999), the title compound was prepared as follows. 12 g(35 mmole) of ethyl 2-{[t-butyl(diphenyl)silyl]oxy}acetate was dissolved in 200 ml of tetrahydrofuran(THF) and 2.2 ml of titaniumtetraisopropoxide was added thereto. To the mixture was slowly added 29.2 ml of ethylmagnesiumbromide(3.0M in THF), and the reaction solution was stirred for 12 hours at room temperature. 20 ml of saturated ammonium chloride was added to stop the reaction. About 150 ml of tetrahydrofuran (THF) used as a solvent was removed by distillation under reduced pressure, and the reaction mixture was extracted twice with 200 ml of ethyl acetate. The ethyl acetate extract was distilled under reduced pressure to give 11.4 g(Yield 100%) of the title compound as a white solid.
  • 1H NMR(CDCl3) δ 0.44 (q, 2H), 0.78 (q, 2H), 1.09 (s, 9H), 3.67 (s, 2H), 7.41 (m, 6H), 7.70(m, 4H)
  • ESI: 344 (M+NH4)+, C20H26O2Si
  • Preparation 2
  • Synthesis of diisopropyl{[1-({[t-butyl(diphenyl)silyl]oxy}methyl)cyclopropyl]oxy}methylphosphonate
  • The compound prepared in Preparation 1 (6.5 g) was dissolved in 10 ml of dimethylformamide(DMF), 32 ml of lithium t-butoxide(1.0M in THF) was added thereto, and the resulting mixture was stirred for 10 minutes. To the mixture was added 7.0 g of diisopropyl bromomethylphosphonate, and then the temperature was raised to 40° C. and the mixture was stirred for 4 hours. Dimethylformamide(DMF) was removed by distillation under reduced pressure, 40 ml of saturated ammonium chloride was added to the residue, which was then extracted with ethyl acetate. The ethyl acetate extract was distilled under reduced pressure and the residue was purified by silica gel column chromatography (eluent: ethyl acetate/n-hexane=1/1, v/v) to give 6.8 g(Yield 70%) of the title compound.
  • 1H NMR(CDCl3) δ 0.53 (m, 2H), 0.88 (m, 2H), 1.07 (s, 9H), 1.29 (t, 12H), 3.78 (s, 2H), 3.98 (d, 6H), 4.75 (m, 2H), 7.40(m, 6H), 7.67(m, 4H)
  • Preparation 3
  • Synthesis of diisopropyl{1-[(hydroxymethyl)cyclopropyl]oxy}methyl phosphonate
  • The compound prepared in Preparation 2 (8.3 g) was dissolved in 100 ml of methanol, 3.1 g of ammonium fluoride was added thereto, and the resulting mixture was heated under reflux for 2 hours. After the reaction was completed, methanol was removed by distillation under reduced pressure and the residue was purified by silica gel column chromatography(eluent: dichloromethane/methanol=20/1, v/v) to give 3.6 g(Yield 82%) of the title compound.
  • 1H NMR(CDCl3) δ 0.60 (t, 2H), 0.87 (t, 2H), 1.28 (d, 12H), 2.5 (br s, 1H), 3.65 (s, 2H), 3.83 (d, 2 H), 4.82 (m, 2H)
  • ESI: 267 (M+1)+, C11H23O4P
  • Preparation 4
  • Synthesis of {1-[(diisopropoxyphosphoryl)methoxy]cyclopropyl}methyl methane-sulfonate
  • The compound prepared in Preparation 3 (1.5 g) was dissolved in 50 ml of dichloromethane, 0.85 ml of triethylamine and 0.84 g of methanesulfonylchloride were added thereto, and the resulting mixture was stirred for 30 minutes at room temperature. Saturated ammonium chloride was added to stop the reaction. The product was extracted with dichloromethane and the dichloromethane extract was concentrated by distillation under reduced pressure. The residue was purified by silica gel column chromatography(eluent: ethyl acetate/n-hexane=1/1, v/v) to give 1.63 g(Yield 81%) of the title compound.
  • 1H NMR(CDCl3) δ 0.77 (m, 2H), 1.09 (m, 2H), 1.32 (m, 12H), 3.10 (s, 3H), 3.82 (m, 2H), 4.33 (s, 2H), 4.71 (m, 2H)
  • Preparation 5
  • Synthesis of diisopropyl({1-(6-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methylphosphonate
  • Figure US20100004440A1-20100107-C00209
  • The compound prepared in Preparation 4 (430 mg) was dissolved in 18 ml of dimethylformamide, 57.6 mg (60% purity) of sodium hydride and 162 mg of adenine were added thereto, and the resulting mixture was heated under reflux over 4 hours. Saturated ammonium chloride was added to stop the reaction. The product was extracted with ethyl acetate, and the ethyl acetate extract was distilled under reduced pressure. The residue was purified by silica gel column chromatography(eluent: dichloromethane/methanol=20/1, v/v) to give 201 mg(Yield 44%) of the title compound.
  • 1H NMR(CDCl3) δ 0.86 (t, 2H), 1.01 (t, 2H), 1.24 (d, 6H), 1.34 (d, 6H), 3.86 (d, 2H), 4.34 (s, 2H), 4.71 (m, 2H), 5.97 (br s, 2H), 8.32 (s, 1H), 8.58 (s, 1H)
  • ESI: 384 (M+1)+, C16H25N5O4P
  • Preparation 6
  • Synthesis of diisopropyl({1-[(2-amino-6-chloro-9H-purin-9-yl)methyl]cyclopropyl}oxy)methylphosphonate
  • Figure US20100004440A1-20100107-C00210
  • The compound prepared in Preparation 4 (1.64 g) was dissolved in 70 ml of dimethylformamide, 219 mg(60% purity) of sodium hydride and 773 mg of 2-amino-6-chloro-9H-purine were added thereto, and the resulting mixture was stirred for 4 hours while heating at a temperature of up to 80° C. Saturated ammonium chloride was added to stop the reaction. The product was extracted with ethyl acetate, and the ethyl acetate extract was distilled under reduced pressure. The residue was purified by silica gel column chromatography(eluent: dichloromethane/methanol=20/1, v/v) to give 765 mg(Yield 40%) of the title compound.
  • 1H NMR(CDCl3) δ 0.80 (t, 2H), 1.02 (t, 2H), 1.27 (d, 6H), 1.28 (d, 6H), 3.82 (d, 2H), 4.21 (s, 2H), 4.68 (m, 2H), 5.13 (br s, 2H), 8.15 (s, 1H)
  • ESI: 418 (M+1)+, C16H25C1N5O4P
  • Preparation 7
  • Synthesis of diisopropyl[(1{[5-methyl-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl]methyl}cyclopropyl)oxy]methylphosphonate
  • Figure US20100004440A1-20100107-C00211
  • The compound prepared in Preparation 4 (118 mg) and thymine were reacted according to the same procedure as Preparation 6 to give 26 mg(Yield 21%) of the title compound.
  • 1H NMR(CDCl3) δ 0.82 (t, 2H), 0.95 (t, 2H), 1.31 (m, 12H), 1.92 (s, 3H), 3.74 (d, 2H), 3.89 (s, 2H), 4.71 (m, 2H), 7.62 (s, 1H), 9.15 (s, 1H)
  • ESI: 375 (M+1)+, C16H27N2O6P
  • Preparation 8
  • Synthesis of 1-({[t-butyl(diphenyl)silyl]oxy}methyl)-2-methylcyclopropanol
  • Figure US20100004440A1-20100107-C00212
  • According to the description in a reference (see: Syn. Lett. 07, 1053-1054, 1999), the title compound was prepared as follows. 50 g(146 mmole) of ethyl 2-{[t-butyl(diphenyl)silyl]oxy}acetate was dissolved in 700 ml of tetrahydrofuran(THF) and 30.0 ml of titaniumtetraisopropoxide was added thereto. To the mixture was slowly added 290 ml of propylmagnesiumchloride(2.0M in THF) at −10° C., and the reaction solution was stirred for 12 hours at room temperature. 200 ml of saturated ammonium chloride was added to stop the reaction. The tetrahydrofuran (THF) used as a solvent was removed by distillation under reduced pressure, and the reaction mixture was extracted twice with 2000 ml of n-hexane. The n-hexane extract was distilled under reduced pressure and purified by silica gel column to give 42 g of the title compound.
  • 1H NMR(CDCl3) δ 0.06 (t, 1H), 0.88 (dd, 2H), 0.97 (d, 3H), 1.09 (s, 9H) 1.1 (m, 1H), 2.78 (s, 1H), 3.70 (d, 1H), 3.86 (d, 1H), 7.41 (m, 6H), 7.70 (m, 4H)
  • ESI: 363 (M+Na)+, C21H28O2Si
  • Preparation 9
  • Synthesis of diisopropyl{[1-({[t-butyl(diphenyl)silyl]oxy}methyl)-2-methyl cyclopropyl]oxy}methylphosphonate
  • Figure US20100004440A1-20100107-C00213
  • The compound prepared in Preparation 8 (4.2 g) was reacted according to the same procedure as Preparation 2 to give 3.3 g of the title compound.
  • 1H NMR(CDCl3) δ 0.04 (t, 1H), 0.96 (dd, 1H), 0.97 (d, 3H), 1.05 (m, 1H), 1.06 (s, 9H), 1.23 (t, 12H), 3.72 (d, 1H), 3.95 (d, 2H), 3.98 (d, 1H), 4.75 (m, 2H), 7.40 (m, 6H), 7.68 (m, 4H)
  • Preparation 10
  • Synthesis of diisopropyl{1-[(hydroxymethyl)-2-methylcyclopropyl]oxy}methylphosphonate
  • Figure US20100004440A1-20100107-C00214
  • The compound prepared in Preparation 9 (3.3 g) was reacted according to the same procedure as Preparation 3 to give 1.7 g of the title compound.
  • 1H NMR(CDCl3) δ 0.03 (t, 1H), 0.95 (dd, 1H), 0.96 (m, 1H), 1.11 (d, 3H), 1.35 (d, 12H), 2.17 (br s, 1H), 3.80 (d, 2H), 3.96 (d, 1H), 4.80 (m, 2H)
  • ESI: 303 (M+Na)+, C12H225O4
  • Preparation 11
  • Synthesis of diisopropyl({1-[(6-amino-9H-purin-9-yl)methyl]-2-methyl cyclopropyl}oxy)methylphosphonate
  • Figure US20100004440A1-20100107-C00215
  • The compound prepared in Preparation 10 (1.5 g) was dissolved in 50 ml of dichloromethane, 0.85 ml of triethylamine and 0.84 g of methanesulfonylchloride were added thereto, and the resulting mixture was stirred for 30 minutes at room temperature. Saturated ammonium chloride was added to stop the reaction. The product was extracted with dichloromethane and the dichloromethane extract was concentrated by distillation under reduced pressure. The residue was used in the next reaction without any purification.
  • 1H NMR(CDCl3) δ 0.42 (m, 1H), 1.12 (d, 3H), 1.25 (m, 1H), 1.32 (m, 12H), 1.33 (m, 1H), 3.10 (s, 3H), 3.76 (m, 2H), 4.31 (d, 1H), 4.71 (d, 1H), 4.76 (m, 2H)
  • The methanesulfonate thus obtained (430 mg) was dissolved in 18 ml of dimethylformamide, and 57.6 mg (60% purity) of sodium hydride and 162 mg of adenine were added thereto. The reaction mixture was refluxed under heating over 4 hours. Saturated ammonium chloride was added to stop the reaction. The product was extracted with ethyl acetate and the ethyl acetate extract was concentrated by distillation under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane/methanol=20/1, v/v) to give 201 mg(Yield 44%) of the title compound.
  • 1H NMR(CDCl3) δ 0.53 (t, 1H), 1.13 (d, 3H), 1.15 (m, 1H), 1.30 (m, 12H), 1.41 (m, 1H), 1.85 (brs, 2H), 3.81 (m, 2H), 4.43 (m, 2H), 4.70 (m, 2H), 5.65 (br s, 2H), 8.26 (s, 1H), 8.34 (s, 1H)
  • ESI: 398 (M+1)+, C17H28N5O4P
  • Preparation 12
  • Synthesis of diisopropyl({1-[(2-amino-6-chloro-9H-purin-9-yl)methyl]-2-methylcyclopropyl}oxy)methylphosphonate
  • Figure US20100004440A1-20100107-C00216
  • The compound prepared in Preparation 10 was reacted according to the same procedure as Preparation 11 except that 6-chloroguanine (2-amino-6-chloro-9H-purine) was used instead of adenine to give the title compound.
  • 1H NMR(CDCl3) δ 0.47 (t, J=6.4 Hz, 1H), 1.12 (m, 4H), 1.24 (dd, J=2.8 Hz, 6.4 Hz, 6H), 1.28 (t, J=6.0 Hz, 6H), 1.38 (m, 1H), 3.80 (m, 2H), 4.28 (m, 2H), 4.68 (m, 2H), 5.13 (brs, 2H), 8.15 (s, 1H)
  • ESI: 432 (M+1)+, C17H27C1N5O4P
  • Preparation 13
  • Synthesis of diisopropyl[(1{[5-methyl-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl]methyl}-2-methylcyclopropyl)oxy]methylphosphonate
  • Figure US20100004440A1-20100107-C00217
  • The compound prepared in Preparation 10 was reacted according to the same procedure as Preparation 11 except that thymine was used instead of adenine to give the title compound.
  • 1H NMR(CDCl3) δ 0.48 (t, 1H), 1.10 (m, 4H), 1.24 (dd, 6H), 1.28 (t, J=6H), 1.38 (m, 1H), 1.92 (s, 3H), 3.80 (m, 2H), 4.28 (m, 2H), 4.68 (m, 2H), 7.62 (s, 1H), 9.15 (s, 1H)
  • ESI: 389 (M+1)+′ C17H29N2O6P
  • Preparation 14
  • Synthesis of 1-(ethoxycarbonyl)cyclopropanecarboxylic acid
  • Figure US20100004440A1-20100107-C00218
  • Diethyl 1,1-cyclopropane dicarboxylate (20 g) was hydrolyzed in 1N NaOH (107 ml) and ethanol (220 ml) for 16 hours, and the ethanol was removed by distillation under reduced pressure. The remaining starting material was removed by using ethyl acetate and the aqueous layer was acidified by 1N HCl. The reaction mixture was extracted with ethyl acetate and distilled under reduced pressure. The residue was purified by silica gel column to give the title compound in a yield of 94%.
  • 1H NMR(CDCl3) δ 1.06 (t, 3H), 1.53 (m, 2H), 1.62 (m, 2H), 4.21 (q, 2H)
  • ESI: 159 (M+1)+ C7H10O4
  • Preparation 15
  • Synthesis of ethyl 1-{[(benzyloxy)carbonyl]amino}cyclopropanecarboxylate
  • Figure US20100004440A1-20100107-C00219
  • The carboxylic acid prepared in Preparation 14 (16 g) was dissolved in dichloromethane, 10.8 ml of oxalyl chloride was added dropwise, and 2 drops of dimethylformamide was added. The reaction mixture was stirred at room temperature for 3 hours and distilled under reduced pressure to give ethoxycarbonyl 1,1-cyclopropane carbonylchloride. This compound, not purified, was dissolved in 30 ml of dimethylformamide and the resulting solution was cooled with water-ice. 36 g of NaN3 was added and the reaction was carried out at room temperature for 3 hours. The reaction solution was extracted with 100 ml of water and 200 ml of diethylether, and the diethylether extract was concentrated to give crude compound which was purified by silica gel column to give an azide compound.
  • 1H NMR(CDCl3) δ 1.28 (t, 3H), 1.54 (m, 4H), 4.19 (q, 2H)
  • To the azide compound thus obtained (13 g) was added dropwise 11 ml of benzyl alcohol and the reaction mixture was heated to 100° C., by which the reactants were vigorously reacted with each other with the generation of gas. The reaction mixture was heated at 100° C. for further 1 hour, cooled to room temperature, and distilled under reduced pressure to remove benzyl alcohol. The residue was purified by silica gel column to give the title compound.
  • 1H NMR(CDCl3) δ 1.19 (m, 5H), 1.54 (m, 2H), 4.11 (m, 2H), 5.15 (br.s, 2H), 7.32 (m, 5H)
  • Preparation 16
  • Synthesis of benzyl 1-{[t-butyl(diphenylsilyl)oxy]methylcyclopropyl}(methyl)carbamate
  • Figure US20100004440A1-20100107-C00220
  • The carboxylate prepared in Preparation 15 (13.2 g) was dissolved in diethylether, to which 1.3 g of LiBH4 dissolved in diethylether was slowly added dropwise. The reaction misture was stirred at room temperature for 16 hours, and 50 ml of methanol and 5 ml of 1N HCl were added dropwise thereto. The reaction mixture was stirred for 2 hours, the precipitate was removed by suction filtration, and the solvent in the filtrate was removed by distillation under reduced pressure. The residue was purified by silica gel column to give benzyl 1-(hydroxymethyl)cyclopropylcarbamate.
  • This compound (9.3 g) was dissolved in dichloromethane, and 4.2 g of imidazole and 13.5 ml of t-butyldiphenylsilylchloride were added in order. The reaction mixture was stirred at room temperature for 4 hours and the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column to give benzyl 1-({[t-butyl(diphenyl)silyl]oxy}methyl)cyclopropylcarbamate.
  • 1H NMR(CDCl3) δ 0.71-1.19 (m, 4H), 1.04 (s, 9H), 3.68 (br.s, 2H), 5.04 (s, 2H), 7.25-7.45 (m, 11H), 7.62 (d, 4H)
  • The carbamate thus obtained (5.5 g) was dissolved in THF, 3.5 ml of methane iodide (MeI) was added dropwise and then 1 g of NaH was added. The reaction mixture was stirred at room temperature for 4 hours and then extracted with 100 ml of diethylether and 100 ml of water. The diethylether extract was concentrated by distillation under reduced pressure and the residue was purified by silica gel column to give the title compound.
  • 1H NMR(CDCl3) δ 0.78-0.84 (m, 4H), 1.03 (s, 9H), 3.03 (s, 3H), 3.55-3.80 (m, 2H), 5.10 (s, 2H), 7.24-7.45 (m, 11H), 7.61 (m, 4H)
  • Preparation 17
  • Synthesis of diisopropyl[1-({[t-butyl(diphenyl)silyl]oxy}methyl)cyclopropyl)(methyl)amino]methylphosphonate
  • Figure US20100004440A1-20100107-C00221
  • The carbamate prepared in Preparation 16 (1.0 g) was dissolved in ethanol, 100 mg of 10% Pd/C was added, and the reaction mixture was subjected to a hydrogenation under hydrogen atmosphere. After the reaction was completed, the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column to give 1-({[t-butyl(diphenyl)silyl]oxy}methyl)-N-methylcyclopropaneamine.
  • 1H NMR(CDCl3) δ 0.36 (m, 2H), 0.65 (m, 2H), 1.05 (s, 9H), 2.36 (s, 3H), 3.57 (s, 2H), 7.37-7.45 (m, 11H), 7.66 (d, 4H)
  • The methylcyclopropaneamine thus obtained (1.0 g) was dissolved in dichloromethane, to which 1.03 ml of diisopropylethylamine and 1.3 ml of (diisopropyl phosphoryl)methyl trifluoromethansulfonate were added dropwise. The reaction mixture was reacted under stirring at room temperature for 4 hours, and then extracted with 100 ml of diethylether and 100 ml of water. The solvent in the diethylether extract was removed by distillation under reduced pressure and the residue was purified by silica gel column to give the title compound.
  • 1H NMR(CDCl3) δ 0.42 (m, 2H), 0.69 (m, 2H), 1.04 (s, 9H), 1.25 (d, 6H), 1.30 (d, 6H), 2.62 (s, 3H), 3.25 (d, 2H), 3.64 (s, 2H), 4.68 (m, 2H), 7.39 (m, 6H), 7.65 (d, 4H)
  • Preparation 18
  • Synthesis of diisopropyl(1-{[(6-amino-9H-purin-9-yl)methyl]cyclopropyl}(methyl)amino)methylphosphonate
  • Figure US20100004440A1-20100107-C00222
  • The compound prepared in Preparation 17 (0.32 g) was dissolved in methanol and 1.5 g of ammonium fluoride was added dropwise. The reaction mixture was reacted under stirring at 60° C. for 24 hours and then the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column to give methylaminediisopropylmethylphosphone 1,1-cyclopropane ethyl alcohol.
  • 1H NMR(CDCl3) δ 0.56 (m, 2H), 0.73 (m, 2H), 1.31 (m, 12H), 2.56 (s, 3H), 3.11 (d, 2H), 3.55 (s, 2H), 4.70 (m, 2H)
  • The compound thus obtained was consecutively reacted according to the same procedure as Preparations 4 and 5 to give the title compound.
  • 1H NMR(CDCl3) δ 0.78 (m, 2H), 0.86 (m, 2H), 1.25 (m, 12H), 2.35 (s, 3H), 4.10 (s, 2H), 4.68 (m, 2H), 5.13 (m, 2H), 8.32 (s, 1H), 8.58 (s, 1H)
  • ESI: 397 (M+1)+, C17H29N6O3P
  • Preparation 19
  • Synthesis of diisopropyl(1-{[(2-amino-6-chloro-9H-purin-9-yl)methyl]cyclopropyl}(methyl)amino)methylphosphonate
  • Figure US20100004440A1-20100107-C00223
  • The compound prepared in Preparation 17 (0.32 g) was dissolved in methanol and 1.5 g of ammonium fluoride was added dropwise. The reaction mixture was reacted under stirring at 60° C. for 24 hours and then the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column to give methylaminediisopropylmethylphosphone 1,1-cyclopropane ethyl alcohol.
  • 1H NMR(CDCl3) δ 0.56 (m, 2H), 0.73 (m, 2H), 1.31 (m, 12H), 2.56 (s, 3H), 3.11 (d, 2H), 3.55 (s, 2H), 4.70 (m, 2H)
  • The compound thus obtained was consecutively reacted according to the same procedure as Preparations 4 and 6 to give the title compound.
  • 1H NMR(400 MHz, CD3OD): δ 0.79 (m, 2H), 0.89 (m, 2H), 1.26 (m, 12H), 2.38 (s, 3H), 2.76 (d, 2H, J=7 Hz), 4.11 (s, 2H), 4.65 (m, 2H), 5.13 (m, 2H), 8.02 (s, 1H)
  • ESI: 431(M+1)+, C17H28C1N6O3P
  • Preparation 20
  • Synthesis of diisopropyl[(1-{[5-methyl-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl]methyl}cyclopropyl)(methyl)amino]methylphosphonate
  • Figure US20100004440A1-20100107-C00224
  • The compound prepared in Preparation 17 (0.32 g) was dissolved in methanol and 1.5 g of ammonium fluoride was added dropwise. The reaction mixture was reacted under stirring at 60° C. for 24 hours and then the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column to give methylaminediisopropylmethylphosphone 1,1-cyclopropane ethyl alcohol.
  • 1H NMR(CDCl3) δ 0.56 (m, 2H), 0.73 (m, 2H), 1.31 (m, 12H), 2.56 (s, 3H), 3.11 (d, 2H), 3.55 (s, 2H), 4.70 (m, 2H)
  • The compound thus obtained was consecutively reacted according to the same procedure as Preparations 4 and 7 to give the title compound.
  • 1H NMR(CDCl3) δ 0.79 (m, 2H), 0.90 (m, 2H), 1.31 (m, 12H), 1.92 (s, 3H), 2.38 (s, 3H), 3.75 (d, 2H), 4.10 (s, 2H), 4.65 (m, 2H), 7.62 (s, 1H), 9.15 (s, 1H)
  • Preparation 21
  • Synthesis of 1,1-cyclopropanedicarboxylic acid
  • Figure US20100004440A1-20100107-C00225
  • In 50% NaOH 187 ml was dissolved 15 g of diethylmalonate at room temperature. Benzyltriethylammoniumchloride (21.3 g) was added and the resulting mixture was stirred for 10 minutes. 1,2-Dibromoethane (12.3 g) was added to the reaction solution and the resulting mixture was stirred for more than 18 hours at room temperature. The reaction mixture was neutralized by adding dropwise conc. sulfuric acid and then extracted with ethyl acetate. The extract was distilled under reduced pressure to give 6.2 g of the title compound as a white solid.
  • 1H NMR(CDCl3) δ 1.88 (s, 4H)
  • Preparation 22
  • Synthesis of [1-({[t-butyl(diphenyl)silyl]oxy}methyl)cyclopropyl]methanol
  • Figure US20100004440A1-20100107-C00226
  • Lithium aluminum hydride (LAH) 15.3 g was dissolved in 39 g of tetrahydrofuran, and 11.7 g of the carboxylic acid prepared in Preparation 21 was slowly added dropwise at 0° C. The reaction solution was refluxed for 17 hours. The reaction was stopped by adding 10% HCl at room temperature and the mixture was extracted with ethyl acetate. The extract was distilled under reduced pressure and the residue was purified by silica gel column to give 8.2 g of diol compound.
  • 1H NMR(CDCl3) δ 0.56 (s, 4H), 2.22 (s, 2H), 3.63 (s, 4H)
  • The compound thus obtained (400 mg) was dissolved in 12 ml of THF, 184 mg of NaH and 1.16 g of t-butyldiphenylsilylchloride (TBDPSCI) were added, and the resulting mixture was refluxed for 6 hours. The reaction was stopped by adding 10 ml of water and the mixture was extracted with ethyl acetate. The extract was distilled under reduced pressure and the residue was purified by silica gel column to give 1.1 g of the title compound.
  • 1H NMR(CDCl3) δ 0.33 (t, 2H), 0.48 (t, 2H), 1.23 (s, 9H), 3.59 (d, 4H), 7.42 (m, 6H), 7.68 (m, 4H)
  • Preparation 23
  • Synthesis of diethyl(E)-2-[1-({[t-butyl(diphenyl)silyl]oxy}methyl)cyclopropyl]ethenylphosphonate
  • Figure US20100004440A1-20100107-C00227
  • The compound prepared in Preparation 22 (2 g) was dissolved in 50 ml of dichloromethane, and 1.03 g of N-methylmorpholine N-oxide and 103 mg of tetrapropylammoniumperruthenate (TPAP) were added thereto at room temperature. The reaction mixture was stirred for about 1 hour at room temperature and the reaction was stopped by adding 20 ml of water. The reaction solution was extracted with dichloromethane and the extract was concentrated under reduced pressure to give 2.0 g of aldehyde compound.
  • 1H NMR(CDCl3) δ 1.03 (s, 9H), 1.04 (t, 2H), 1.05 (t, 2H), 3.94 (s, 2H), 7.37 (m, 6H), 7.64 (m, 4H), 9.10 (s, 1H)
  • Tetraethylmethylene diphosphonate (1.7 g) was dissolved in 60 ml of tetrahydrofuran (THF). At −78° C., 264 mg of NaH was added, the resulting mixture was stirred for 20 minutes, and then 1.9 g of the aldehyde compound as obtained above was added. The reaction solution was stirred at room temperature for 1 hour, and the reaction was stopped by adding 20 ml of water. The reaction solution was extracted with ethyl acetate and the extract was concentrated under reduced pressure. The residue was purified by silica gel column to give 2.32 g of the title compound.
  • 1H NMR(CDCl3) δ 0.76 (t, 2H), 0.81 (t, 2H), 1.04 (s, 9H), 1.31 (t, 6H), 3.71 (s, 2H), 4.05 (m, 4H), 5.70 (m, 1H), 6.42 (m, 1H), 7.43 (m, 6H), 7.64 (d, 4H)
  • ESI: 501 (M+1)+′ C28H41O4PSi
  • Preparation 24
  • Synthesis of diethyl 2-[1-(hydroxymethyl)cyclopropyl]ethenylphosphonate
  • Figure US20100004440A1-20100107-C00228
  • The compound prepared in Preparation 23 was reacted according to the same procedure as Preparation 3 to give the title compound.
  • 1H NMR(CDCl3) δ 0.76 (t, 2H), 0.81 (t, 2H), 1.04 (s, 9H), 1.31 (t, 6H), 3.71 (s, 2H), 4.05 (m, 4H), 5.70 (m, 1H), 6.42 (m, 1H), 7.43 (m, 6H), 7.64 (d, 4H)
  • ESI: 501 (M+1)+′ C28H41O4PSi
  • Preparation 25
  • Synthesis of diethyl 2-{1-[(6-amino-9H-purin-9-yl)methyl]cyclopropyl}ethenylphosphonate
  • Figure US20100004440A1-20100107-C00229
  • The compound prepared in Preparation 24 was reacted according to the same procedure as Preparations 4 and 5 to give the title compound.
  • 1H NMR(CDCl3) δ 1.07 (t, 2H), 1.19 (t, 2H), 1.22 (t, 6H), 3.93 (s, 4H), 4.33 (s, 2H), 5.55 (s, 2H), 5.63 (m, 1H), 6.49 (m, 1H), 7.88 (s, 1H), 8.37 (s, 1H)
  • ESI:352 (M+1)+′ C15H22N5O3P
  • Preparation 26
  • Synthesis of diethyl 2-{1-[(2-amino-6-chloro-9H-purin-9-yl)methyl]cyclopropyl}ethenylphosphonate
  • Figure US20100004440A1-20100107-C00230
  • The compound prepared in Preparation 24 was reacted according to the same procedure as Preparations 4 and 6 to give the title compound.
  • 1H NMR(CDCl3) δ 1.06 (t, 2H), 1.15 (t, 2H), 1.23 (t, 6H), 3.93 (s, 4H), 4.18 (s, 2H), 5.12 (s, 2H), 5.59 (m, 1H), 6.58 (m, 1H), 7.81 (s, 1H)
  • ESI:386 (M+1)+′ C15H21C1N5O3P
  • Preparation 27
  • Synthesis of diethyl 2-(1-{[5-methyl-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl]methyl}cyclopropyl)ethenylphosphonate
  • Figure US20100004440A1-20100107-C00231
  • The compound prepared in Preparation 24 was reacted according to the same procedure as Preparations 4 and 7 to give the title compound.
  • 1H NMR(CDCl3) δ 0.93 (t, 2H), 1.01 (t, 2H), 1.24 (t, 6H), 1.92 (s, 3H), 3.91 (s, 2H), 3.96 (m, 4H), 5.49 (m, 1H), 5.87 (m, 1H), 7.62 (s, 1H). 9.15 (s, 1H)
  • ESI:343 (M+1)+′ C15H23N2O5P
  • Preparation 28
  • Synthesis of 1-({[t-butyl(diphenyl)silyl]oxy}methyl)-2,2-dimethylcyclopropanol
  • Figure US20100004440A1-20100107-C00232
  • According to the description in a reference (see: Syn. Lett. 07, 1053-1054, 1999), the title compound was prepared as follows. 10 g(29 mmole) of ethyl 2-{[t-butyl(diphenyl)silyl]oxy}acetate was dissolved in 100 ml of tetrahydrofuran (THF) and 6.0 ml of titaniumtetraisopropoxide was added thereto. To the mixture was slowly added 37 ml of isobutylmagnesiumbromide(2.0M in THF) at −10° C., and the reaction solution was stirred for 12 hours at room temperature. 50 ml of saturated ammonium chloride was added to stop the reaction. The tetrahydrofuran (THF) used as a solvent was removed by distillation under reduced pressure, and the reaction mixture was extracted twice with 500 ml of n-hexane. The n-hexane extract was distilled under reduced pressure and purified by silica gel column to give 5.0 g of the title compound.
  • 1H NMR(CDCl3) δ 0.25 (d, 1H), 0.51 (d, 2H), 0.99 (s, 3H), 1.07 (s, 9H), 1.22 (s, 3H), 3.71 (d, 1H), 3.91 (d, 1H), 7.41 (m, 6H), 7.70 (m, 4H)
  • ESI: 355 (M+1)+, C22H30O2Si
  • Preparation 29
  • Synthesis of diisopropyl{[1-({[t-butyl(diphenyl)silyl]oxy}methyl)-2,2-dimethyl cyclopropyl]oxy}methylphosphonate
  • Figure US20100004440A1-20100107-C00233
  • The compound prepared in Preparation 28 was reacted according to the same procedure as Preparation 2 to give the title compound.
  • 1H NMR(CDCl3) δ 0.29 (d, 1H), 0.60 (d, 1H), 1.06 (s, 3H), 1.09 (s, 9H), 1.27 (s, 3H), 1.30 (m, 12H), 3.75 (m, 2H), 3.92 (m, 2H), 4.72 (m, 2H), 7.41 (m, 6H), 7.67 (m, 4H)
  • ESI: 519 (M+1)+, C28H43O5PSi
  • Preparation 30
  • Synthesis of diisopropyl{1-(hydroxymethyl)-2,2-dimethylcyclopropyl]oxy}methylphosphonate
  • Figure US20100004440A1-20100107-C00234
  • The compound prepared in Preparation 29 was reacted according to the same procedure as Preparation 3 to give the title compound.
  • 1H NMR(CDCl3) δ 0.39 (d, 1H), 0.59 (d, 1H), 1.13 (s, 3H), 1.21 (s, 3H), 1.33 (d, 12H), 3.76 (m, 2H), 3.86 (m, 2H), 4.76 (m, 2H)
  • ESI: 295 (M+1)+, C13H27O4P
  • Preparation 31
  • Synthesis of diisopropyl({1-[(6-amino-9H-purin-9-yl)methyl]-2,2-dimethyl cyclopropyl}oxy)methylphosphonate
  • Figure US20100004440A1-20100107-C00235
  • The compound prepared in Preparation 30 was reacted according to the same procedure as Preparation 11 to give the title compound.
  • 1H NMR(500 MHz, CDCl3): δ 0.62 (d, J=5.9 Hz, 1H), 0.81 (d, J=5.9 Hz, 1H), 1.10 (s, 3H), 1.23 (m, 15H), 3.72 (dd, J=15.1, 11.0 Hz, 1H), 3.85 (dd, J=15.1, 5.5 Hz, 1H), 4.28 (d, J=15.1 Hz, 1H), 4.58 (d, J=15.1 Hz, 1H), 4.68 (m, 2H), 5.79 (bs, 2H), 8.19 (s, 1H), 8.32 (s, 1H)
  • ESI: 412 (M+1)+, C18H30N5O4P
  • Preparation 32
  • Synthesis of diisopropyl({1-[(2-amino-6-iodo-9H-purin-9-yl)methyl]-2,2-dimethylcyclopropyl}oxy)methylphosphonate
  • Figure US20100004440A1-20100107-C00236
  • The compound prepared in Preparation 30 was reacted according to the same procedure as Preparation 12 except that 6-iodoguanine was used instead of 6-chloroguanine to give the title compound.
  • 1H NMR(500 MHz, CDCl3): δ 0.58 (d, J=6.4 Hz, 1H), 0.80 (d, J=6.4 Hz, 1H), 1.10 (s, 3H), 1.24 (m, 8H), 3.72 (dd, J=13.0, 11.0 Hz, 1H), 3.88 (dd, J=13.0, 9.3 Hz, 1H) 4.08 (d, J=15.1 Hz, 1H), 4.47 (d, J=15.1 Hz, 1H), 4.67 (m, 2H), 5.05 (bs, 1H), 8.10 (s, 1H)
  • ESI: 538 (M+1)+, C18H29IN5O4P
  • Preparation 33
  • Synthesis of diisopropyl[(1{[5-methyl-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl]methyl}-2,2-dimethylcyclopropyl)oxy]methylphosphonate
  • Figure US20100004440A1-20100107-C00237
  • The compound prepared in Preparation 30 was reacted according to the same procedure as Preparation 13 to give the title compound.
  • 1H NMR(CDCl3) δ 0.58 (d, 1H), 0.80 (d, 1H), 1.10 (s, 3H), 1.24 (dd, 6H), 1.28 (t, 6H), 1.58 (s, 3H), 1.92 (s, 3H), 3.72 (dd, 1H), 3.88 (dd, 1H), 4.08 (d, 1H), 4.47 (d, 1H), 4.67 (m, 2H), 7.62 (s, 1H), 9.15 (s, 1H)
  • ESI: 403 (M+1)+′ C18H31N2O6P
  • Preparation 34
  • Synthesis of 1-[1-({[t-butyl(diphenyl)silyl]oxy}methyl)cyclopropyl]-1-methyl alcohol
  • Figure US20100004440A1-20100107-C00238
  • 6 g of the compound prepared in Preparation 22 was dissolved in 150 ml of dichloromethane. 3.0 g of N-oxide and 103 mg of tetrapropylammoniumperruthenate (TPAP) were added thereto at room temperature. The reaction mixture was stirred for about 1 hour at room temperature and quenched by adding 20 ml of water. The reaction mixture was extracted with dichloromethane and the extract was concentrated under reduced pressure to give 6.0 g of aldehyde compound which went to next reaction without further purification.
  • 5.23 g of the aldehyde was dissolved in 350 ml of THF. The solution was cooled to −78° C. and 10.3 ml of methylmagnesiumbromide (3.0M solution) was slowly added to the solution and then, stirred for 1 hour at room temperature. The reaction mixture was quenched by 0.5 ml of water and 0.5 ml of methanol and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: ethyl acetate/n-hexane=1/8, v/v) to 3.57 g of title compound.
  • 1H NMR(CDCl3) δ 0.22 (m, 1H), 0.39 (m, 2H), 0.61 (m, 1H), 1.06 (s, 9H), 1.24 (d, 3H), 3.3 (d, 1H), 3.47 (s, 2H), 3.9 (d, 1H), 7.43 (m, 6H), 7.64 (m, 6H)
  • Preparation 35
  • Synthesis of diethyl (E)-2-1-[1-({[t-butyl(diphenyl)silyl]oxy}methyl)cyclopropyl]-1-propenylphosphonate
  • Figure US20100004440A1-20100107-C00239
  • 4 g of the compound prepared in preparation 34 was dissolved in 10 ml of dichloromethane. 2.1 g of n-morpholine N-oxide and 209 mg of tetrapropylammoniumperruthenate (TPAP) were added thereto at room temperature. The reaction mixture was stirred for about 1 hour at room temperature and quenched by adding 20 ml of water. The reaction mixture was extracted with dichloromethane and the extract was concentrated under reduced pressure to give 4.0 g of compound which went to next reaction without further purification.
  • Tetraethylmethylene diphosphonate (2.7 g) was dissolved in 30 ml of tetrahydrofuran (THF) at −78 and 4 ml of n-butyllithium was added. The resulting mixture was stirred for 20 minutes, and then 1.0 g of the ketone compound as obtained above was added. The reaction mixture was stirred at room temperature for 1 hour and was stopped by adding 20 ml of water. The reaction mixture was extracted with ethyl acetate and concentrated under reduced pressure. The residue was purified by silica gel column to give 654 mg of the title compound.
  • 1H NMR(CDCl3) δ 0.58 (m, 1H), 0.69 (m, 2H), 1.02 (s, 9H), 1.20 (t, 6H), 2.09 (d, 3H), 3.59 (s, 2H), 4.05 (m, 4H), 5.61 (d, 1H), 7.38 (m, 6H), 7.63 (d, 4H)
  • Example 1 Synthesis of ({1-[(6-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl phosphonic acid (Compound 1)
  • The compound prepared in Preparation 5 (159 mg) was dissolved in 15 ml of dichloromethane, 1.27 g of trimethylsilylbromide was added thereto, and the resulting mixture was heated under reflux for 18 hours. After the completion of reaction, the reaction mixture was extracted with water, and the water extract was distilled under reduced pressure. The residue was purified by high performance liquid chromatography (HPLC) to give 0.89 g(Yield 90%) of the title compound as a white powder.
  • 1H NMR(MeOH-d4) δ 1.02 (d, 4H), 3.95 (d, 2H), 4.55 (s, 2H), 8.40 (s, 1H), 8.55 (s, 1H)
  • ESI: 300 (M+1)+, C10H14N5O4P
  • Example 2 Synthesis of 3-[({1-[(6-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate (Compound 2)
  • The title compound was prepared according to the method known in a reference(see: J. Med. Chem., 37(12), 1857 (1994)) and U.S. Pat. No. 5,663,159 (1998).
  • The compound prepared in Example 1 (1.00 g) was dissolved in 150 ml of dry dimethylformamide, and 2.08 g(7.32 mmol) of N,N′-dicyclohexyl-4-morpholine-carboxamidine and 2.75 g(18.3 mmol) of chloromethyl pivalate were added thereto. When the reaction mixture became homogeneous after about 1 hour, it was stirred for 5 days at room temperature. The reaction solution was filtered, the filtrate was concentrated under reduced pressure, and the residue was fractionated with 50 ml of water and 50 ml of toluene to separate the organic layer. The aqueous layer was extracted twice with 50 ml of toluene. The combined organic layers were concentrated under reduced pressure. The residue was purified by column chromatography(eluent: methanol/dichloromethane=1/20, v/v) to give 0.59 g(Yield 32%) of the title compound as a white solid.
  • 1H NMR(500 MHz, CDCl3) δ 0.91 (m, 2H), 1.12 (m, 2H), 1.20 (m, 18H), 1.90 (br s, 2H), 3.90 (d, 2H), 4.32 (s, 2H), 5.65 (m, 4H), 8.14 (s, 1H), 8.31 (s, 1H)
  • ESI: 528 (M+1)+, C22H34N5O8P
  • Example 3 Synthesis of ({1-[(2-amino-6-chloro-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl phosphonic acid(Compound 3)
  • The compound prepared in Preparation 6 (73 mg) was reacted according to the same procedure as Example 1 to give 46 mg (Yield 80%) of the title compound.
  • 1H NMR(MeOH-d4) δ 1.00 (s, 2H), 1.07 (s, 2H), 3.94 (d, 2H), 4.52 (s, 2H), 9.50 (s, 1H)
  • ESI: 334 (M+1)+, C10H13C1N5O4P
  • Example 4 Synthesis of ({1-[(2-amino-6-hydroxy-9H-purin-9-yl)methyl]cyclopropyl}oxy)methylphosphonic acid(Compound 5)
  • The compound prepared in Example 3 (41 mg) was dissolved in 5 ml of 2N hydrochloric acid and heated under reflux for 6 hours. Water was removed by distillation under reduced pressure to give 37 mg(Yield 95%) of the title compound as a white solid.
  • 1H NMR(MeOH-d4) δ 0.98 (m, 2H), 1.06 (m, 2H), 3.92 (d, 2H), 4.45 (s, 2H), 9.20 (s, 1H)
  • ESI: 316 (M+1)+, C10H14N5O5P
  • Example 5 Synthesis of ({1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl phosphonic acid(Compound 9)
  • The compound prepared in Preparation 6 (150 mg) was dissolved in 15 ml of tetrahydrofuran, 15 mg of 5% palladium/carbon was added thereto, and the compound was reduced under 1 atm of hydrogen atmosphere for 18 hours. After completion of reaction, palladium/carbon was removed by suction filtration and the filtrate was distilled under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane/methanol=20/1, v/v) to give 130 mg of diisopropyl compound(ESI: 384(M+1)+, C16H26N5O4P). This compound was treated with trimethylsilylbromide according to the same procedure as Example 1 to give 91 mg(Yield 90%) of the title compound.
  • 1H NMR(MeOH-d4) δ 0.94 (m, 2H), 1.03 (m, 2H), 3.93 (d, 2H), 4.40 (s, 2H), 8.66 (s, 1H), 8.74 (s, 1H)
  • ESI: 300 (M+1)+, C10H14N5O4P
  • Example 6 Synthesis of 3-[({1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate(Compound 10)
  • The compound prepared in Example 5 was reacted according to the same procedure as Example 2 to give the title compound.
  • 1H NMR(CDCl3-d4) δ 0.90 (m, 2H), 1.05 (m, 2H), 1.20 (m, 18H), 3.96 (d, 2H), 4.22 (s, 2H), 5.65 (m, 4H), 8.03 (s, 1H), 8.69 (s, 1H)
  • ESI: 528 (M+1)+, C22H34N5O8P
  • Example 7 Synthesis of ({1-[(2-amino-6-cyclopropylamino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methylphosphonic acid(Compound 11)
  • The compound prepared in Preparation 6 (200 mg) was dissolved in 20 ml of ethanol, 53 ml of triethylamine and 82 mg of cyclopropylamine were added thereto, and the resulting mixture was heated under reflux for 18 hours. Water was added to stop the reaction, and the product was extracted with ethyl acetate. The ethyl acetate extract was concentrated by distillation under reduced pressure and the residue was purified by silica gel column chromatography(eluent: dichloromethane/methanol=20/1, v/v) to give 178 mg(Yield 85%) of the diisopropyl compound.
  • 1H NMR(CDCl3) δ 0.59 (t, 2H), 0.83 (m, 4H), 1.00 (t, 2H), 1.24 (d, 6H), 1.29 (d, 6H), 3.0 (brs, 1H), 3.80 (d, 2H), 4.15 (s, 2H), 4.70 (m, 2H), 4.71 (brs, 2H), 5.71 (s, 1H), 7.68 (s, 1H)
  • The compound thus obtained was treated with trimethylsilylbromide according to the same procedure as Example 1 to give 128 mg(Yield 90%) of the title compound.
  • 1H NMR(MeOH-d4) δ 0.86 (m, 2H), 0.94 (m, 2H), 1.02 (m, 2H),1.07 (m, 2H), 2.90 (br s, 1H), 3.93 (d, 2H), 4.39 (s, 2H), 8.43 (br s, 1H)
  • ESI: 355 (M+1)+, C13H19N6O4P
  • Example 8 Synthesis of ({1-[(2-amino-6-ethylamino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methylphosphonic acid(Compound 13)
  • The compound prepared in Preparation 6 (115 mg) was dissolved in 2 ml of ethanol, 31 ml of triethylamine and 0.07 ml of ethylamine were added thereto, and the resulting mixture was heated under reflux for 18 hours. Water was added to stop the reaction, and the product was extracted with ethyl acetate. The ethyl acetate extract was concentrated by distillation under reduced pressure and the residue was purified by silica gel column chromatography(eluent: dichloromethane/methanol=20/1, v/v) to give 104 mg(Yield 89%) of the diisopropyl compound.
  • 1H NMR(CDCl3) δ 0.82 (m, 2H), 1.00 (m, 2H), 1.24 (d, 6H), 1.27 (t, 3H), 1.29 (d, 6H), 3.60 (brs, 2H), 3.81 (d, 2H), 4.15 (s, 2H), 4.65 (m, 4H), 5.50 (br s, 1H), 7.78 (s, 1H)
  • The compound thus obtained was reacted according to the same procedure as Example 1 to give 75 mg(Yield 90%) of the title compound.
  • 1H NMR(MeOH-d4) δ 0.89 (m, 2H), 1.04 (m, 2H), 1.31 (t, 3H), 3.59 (br s, 2H), 3.92 (d, 2H), 4.35 (s, 2H), 9.95 (br s, 1H)
  • ESI: 343 (M+1)+, C13H19N6O4P
  • Example 9 Synthesis of [(1-{[2-amino-6-(dimethylamino)-9H-purin-9-yl]methyl}cyclopropyl)oxy]methylphosphonic acid(Compound 15)
  • The compound prepared in Preparation 6 (115 mg) was dissolved in 20 ml of ethanol, 38.6 ml of triethylamine and 1.74 ml of N,N-dimethylamine were added thereto, and the resulting mixture was heated under reflux for 18 hours. Water was added to stop the reaction, and the product was extracted with ethyl acetate. The ethyl acetate extract was concentrated by distillation under reduced pressure and the residue was purified by silica gel column chromatography(eluent: dichloromethane/methanol=20/1, v/v) to give 119 mg(Yield 81%) of the diisopropyl compound.
  • 1H NMR(CDCl3) δ 0.75 (t, 2H), 0.93 (t, 2H), 1.16 (d, 6H), 1.22 (d, 6H), 3.3 (brs, 6H), 3.74 (d, 2H), 4.09 (s, 2H), 4.60 (m, 2H), 4.69 (brs, 2H), 7.68 (s, 1H)
  • The compound thus obtained was reacted according to the same procedure as Example 1 to give 86 mg(Yield 90%) of the title compound.
  • 1H NMR(MeOH-d4) δ 0.89 (m, 2H), 1.05 (m, 2H), 3.30 (br s, 6H), 3.90 (d, 2H), 4.37 (s, 2H), 7.92 (br s, 1H)
  • ESI: 343 (M+1)+, C12H19N6O4P
  • Example 10 Synthesis of [(1-{[2-amino-6-(isopropylamino)-9H-purin-9-yl]methyl}cyclopropyl)oxy]methylphosphonic acid(Compound 17)
  • The compound prepared in Preparation 6 (133 mg) was dissolved in 20 ml of ethanol, 0.049 ml of triethylamine and 0.082 ml of isopropylamine were added thereto, and the resulting mixture was heated under reflux for 18 hours. Water was added to stop the reaction, and the product was extracted with ethyl acetate. The ethyl acetate extract was concentrated by distillation under reduced pressure and the residue was purified by silica gel column chromatography(eluent: dichloromethane/methanol=20/1, v/v) to give 95 mg(Yield 68%) of the diisopropyl compound.
  • 1H NMR(CDCl3) δ 0.83 (m, 2H), 0.98 (m, 2H), 1.28 (m, 18H), 3.79 (d, 2H), 4.15 (s, 2H), 4.60 (br s, 1H), 4.68 (s, 2H), 4.70 (m, 2H), 5.40 (br s, 1H), 7.77 (s, 1H)
  • The compound thus obtained was reacted according to the same procedure as Example 1 to give 72 mg(Yield 91%) of the title compound.
  • 1H NMR(MeOH-d4) δ 0.89 (m, 2H), 1.05 (m, 2H), 1.34 (d, 6H), 3.30 (br s, 1H), 3.90 (d, 2H), 4.36 (s, 2H), 8.01 (br s, 1H)
  • ESI: 357 (M+1)+, C12H19N6O4P
  • Example 11 Synthesis of ({1-[(2,6-diamino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methylphosphonic acid(Compound 19)
  • The compound prepared in Preparation 4 (246 mg) and 2,6-diaminopurine were reacted according to the same procedure as Preparation 5 to give 78.5 mg(Yield 29%) of the diisopropyl compound.
  • 1H NMR(CDCl3) δ 0.85 (t, 2H), 1.00 (t, 2H), 1.25 (d, 6H), 1.29 (d, 6H), 1.83 (brs, 2H), 3.82 (d, 2H), 4.15 (s, 2H), 4.68 (m, 2H), 5.39 (d, 2H), 7.85 (s, 1H)
  • ESI: 399 (M+1)+, C16H27N6O4P
  • The compound thus obtained was reacted according to the same procedure as Example 1 to give 72 mg(Yield 91%) of the title compound.
  • 1H NMR(DMSO-d6+CF3COOH) δ 0.70 (m, 2H), 0.82 (m, 2H), 3.58 (d, 2H), 4.21 (s, 2H), 8.16 (br s, 1H)
  • ESI: 315 (M+1)+, C10H15N6O4P
  • Example 12 Synthesis of ({1-[(2-amino-6-ethoxy-9H-purin-9-yl)methyl]cyclopropyl}oxy)methylphosphonic acid (Compound 23)
  • 6-Chloroguanine derivative prepared in Preparation 6 (100 mg) was dissolved in 10 ml of ethanol, 32 ml of triethylamine and 53 mg of sodium methoxide were added, and the resulting mixture was refluxed for 4 hours. The reaction was stopped by adding 10 ml of water. The reaction solution was extracted with dichloromethane and distilled under reduced pressure. The residue was purified by silica gel column to give a compound wherein 6-position of guanine was substituted by ethoxy group.
  • 1H NMR(CDCl3) δ 0.83 (t, 2H), 1.00 (t, 2H), 1.24-1.28 (m, 12H), 1.45 (t, 3H), 3.82 (d, 2H), 4.21 (s, 2H), 4.53 (m, 2H), 4.67 (m, 1H), 5.76 (s, 2H), 7.90 (s, 1H)
  • The compound thus obtained was reacted according to the same procedure as Example 1 to give the title compound.
  • 1H NMR(MeOH-d4) δ 0.99 (t, 2H), 1.06 (t, 2H), 1.48 (t, 3H), 3.91 (d, 2H), 4.51 (s, 2H), 4.65 (m, 2H), 9.18 (s, 1H)
  • ESI: 344 (M+1)+, C12H18N5O5P
  • Example 13 Synthesis of ({1-[(2-amino-6-methyl-9H-purin-9-yl)methyl]cyclopropyl}oxy)methylphosphonic acid(Compound 25)
  • 10 ml flask was dried under vacuum and 53 mg(0.238 mmol) of zinc bromide was introduced bit by bit under nitrogen atmosphere. 2 ml of dry tetrahydrofuran was added dropwise thereto, the temperature was lowered to −78° C., 0.08 ml (20.238 mmol) of methylmagnesium bromide was added, and the resulting mixture was stirred for 1 hour. After the reaction mixture was warmed to room temperature, about 10 mol % of palladiumtetrakistriphenylphosphine was added bit by bit. 50 mg(0.119 mmol) of the compound prepared in Preparation 6 in 1 ml of tetrahydrofuran was added to the above reaction solution dropwise. The resulting mixture was heated for 1 hour. The solvent was removed by distillation under reduced pressure, the residue was participated with water and ethyl acetate, and the organic layer was concentrated by distillation under reduced pressure. The residue was purified by silica gel column chromatography(eluent: methylene chloride/methanol=90/10, v/v) to give 20 mg(Yield 42%) of the diisopropyl compound.
  • 1H NMR(MeOH-d4) δ 0.95 (m, 2H), 0.98(m, 2H), 1.17(d, 6H), 1.23 (d, 6H), 2.59(s, 3H), 4.02(s, 1H), 4.10(s, 1H), 4.32(s, 2H), 4.59(m, 2H), 8.12(s, 1H)
  • ESI: 398 (M+1)+, C17H28N5O4P
  • The compound thus obtained was reacted according to the same procedure as Example 1 to give 8.0 mg(Yield 50%) of the title compound.
  • 1H NMR(D2O) δ 0.87 (m, 2H), 1.02 (m, 2H), 3.79 (s, 1H), 3.81 (s, 1H), 4.53 (s, 2H), 8.25 (s, 1H)
  • ESI: 314 (M+1)+, C11H16N5O4P
  • Example 14 Synthesis of [(1{[5-methyl-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl]methyl}cyclopropyl)oxy]methylphosphonic acid(Compound 31)
  • The compound prepared in Preparation 7 (19 mg) was reacted according to the same procedure as Example 1 to give 14 mg(Yield 95%) of the title compound.
  • ESI: 291 (M+1)+, C10H11N2O6P
  • 1H NMR(MeOH-d4) δ 0.82 (t, 2H), 0.97 (t, 2H), 1.87 (s, 3H), 3.83 (d, 2H), 3.97 (s, 2H), 7.55 (s, 1H)
  • Example 15 Synthesis of [(1-{[2-amino-6-(4-morpholinyl)-9H-purin-9-yl]methyl}cyclopropyl)oxy]methylphosphonic acid(Compound 37)
  • The compound prepared in Preparation 6 (134 mg) was dissolved in 20 ml of ethanol, 0.049 ml of triethylamine and 0.085 ml of morpholine were added thereto, and the resulting mixture was heated under reflux for 18 hours. Water was added to stop the reaction, and the product was extracted with ethyl acetate. The ethyl acetate extract was concentrated by distillation under reduced pressure and the residue was purified by silica gel column chromatography(eluent: dichloromethane/methanol=20/1, v/v) to give 66 mg(Yield 44%) of the diisopropyl compound.
  • 1H NMR(CDCl3) δ 0.83 (m, 2H), 0.99 (m, 2H), 1.24 (d, 6H), 1.30 (d, 6H), 3.79 (m, 6H), 4.18 (s, 2H), 4.21 (br s, 4H), 4.67 (m, 2H), 4.80 (br s, 2H), 7.78 (s, 1H)
  • ESI: 469 (M+1)+, C20H33N6O5P
  • The compound thus obtained was treated with trimethylsilylbromide according to the same procedure as Example 1 to give 49 mg(Yield 91%) of the title compound.
  • 1H NMR(MeOH-d4) δ 0.89 (m, 2H), 1.07 (m, 2H), 3.81 (m, 4H), 3.92 (d, 2H), 4.40(br s, 6H), 7.87 (s, 1H)
  • ESI: 384 (M+1)+, C14H21N6O5P
  • Example 16 Synthesis of [(1-{[2-amino-6-(1-piperidinyl)-9H-purin-9-yl]methyl}cyclopropyl)oxy]methylphosphonic acid(Compound 39)
  • The compound prepared in Preparation 6 (154 mg) was dissolved in 20 ml of ethanol, 0.049 ml of triethylamine and 0.11 ml of piperidine were added thereto, and the resulting mixture was heated under reflux for 18 hours. Water was added to stop the reaction, and the product was extracted with ethyl acetate. The ethyl acetate extract was concentrated by distillation under reduced pressure and the residue was purified by silica gel column chromatography(eluent: dichloromethane/methanol=20/1, v/v) to give 123 mg (Yield 72%) of the diisopropyl compound.
  • 1H NMR(CDCl3) δ 0.80 (m, 2H), 0.99 (m, 2H), 1.22 (d, 6H), 1.26 (d, 6H), 1.63 (m, 4H), 1.67 (m, 2H), 3.78 (d, 2H), 4.14 (s, 6H), 4.54 (br s, 2H), 4.65 (m, 2H), 7.72 (s, 1H) ESI: 467 (M+1)+, C21H35N6O4P
  • The compound thus obtained was reacted according to the same procedure as Example 1 to give 87 mg(Yield 91%) of the title compound.
  • 1H NMR(MeOH-d4) δ 0.89 (m, 2H), 1.06 (m, 2H), 1.73 (m, 4H), 1.79 (m, 2H), 3.90 (d, 2H), 4.37 (s, 2H), 4.43(br s, 4H), 7.89 (s, 1H)
  • ESI: 383 (M+1)+, C15H23N6O4P
  • Example 17 Synthesis of [(1-{[2-amino-6-(4-methyl-1-piperazinyl)-9H-purin-9-yl]methyl}cyclopropyl)oxy]methylphosphonic acid(Compound 41)
  • The compound prepared in Preparation 6 (128 mg) was dissolved in 20 ml of ethanol, 0.10 ml of 4-methyl-1-piperazine was added thereto, and the resulting mixture was heated under reflux for 18 hours. Water was added to stop the reaction, and the product was extracted with ethyl acetate. The ethyl acetate extract was concentrated by distillation under reduced pressure and the residue was purified by silica gel column chromatography (eluent: dichloromethane/methanol=20/1, v/v) to give 123 mg(Yield 83%) of the diisopropyl compound.
  • 1H NMR(CDCl3) δ 0.80 (m, 2H), 0.98 (m, 2H), 1.21 (d, 6H), 1.27 (d, 6H), 2.30 (s, 3H), 2.48 (m, 4H), 3.78 (d, 2H), 4.13 (s, 2H), 4.22 (br s, 4H), 4.57 (s, 2H), 4.66 (m, 2H), 7.73 (s, 1H)
  • ESI: 482 (M+1)+, C21H36N7O4P
  • The compound thus obtained was reacted according to the same procedure as Example 1 to give 87 mg(Yield 85%) of the title compound.
  • 1H NMR(MeOH-d4) δ 0.89 (m, 2H), 1.07 (m, 2H), 3.00 (s, 3H), 3.72 (m, 4H), 3.91 (d, 2H), 4.45 (s, 2H), 4.89 (m, 2H), 5.70 (br, 2H), 7.91 (s, 1H)
  • ESI: 398 (M+1)+, C15H24N7O4P
  • Example 18 Synthesis of [(1-{[2-amino-6-(1-pyrrolidinyl)-9H-purin-9-yl]methyl}cyclopropyl)oxy]methyl phosphonic acid (Compound 43)
  • The compound prepared in Preparation 6 (122 mg) was dissolved in 20 ml of ethanol, 0.07 ml of pyrrolidine was added thereto, and the resulting mixture was heated under reflux for 18 hours. Water was added to stop the reaction, and the product was extracted with ethyl acetate. The ethyl acetate extract was concentrated by distillation under reduced pressure and the residue was purified by silica gel column chromatography(eluent: dichloromethane/methanol=20/1, v/v) to give 110 mg(Yield 83%) of the diisopropyl compound.
  • 1H NMR(CDCl3) δ 0.78 (m, 2H), 0.96 (m, 2H), 1.20 (d, 6H), 1.26 (d, 6H), 2.00 (br s, 4H), 3.60 (br, 3H), 3.78 (d, 2H), 4.09 (br, 2H), 4.12 (s, 2H), 4.63 (m, 2H), 7.69 (s, 1H)
  • ESI: 453 (M+1)+, C20H33N6O4P
  • The compound thus obtained was reacted according to the same procedure as Example 1 to give 76 mg(Yield 85%) of the title compound.
  • 1H NMR(MeOH-d4) δ 0.94 (m, 2H), 1.03 (m, 2H), 2.15 (m, 4H), 3.76 (m, 2H), 3.91 (d, 2H), 4.18 (m, 2H), 4.40 (s, 2H), 5.70 (br, 2H), 8.42 (s, 1H)
  • ESI: 369 (M+1)+, C14H21N6O4P
  • Example 19 Synthesis of 3-[({1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-9-methyl-3,7-dioxo-2,4,6-trioxa-385-phosphadec-1-yl 3-methylbutanoate (Compound 74)
  • The compound prepared in Example 5 (100 mg) was dissolved in dimethylformamide (2 ml) and then reacted with chloromethyl 3-methylbutyrate in the presence of triethylamine (3 equivalents) at room temperature for 24 hours. The resulting product was purified by silica gel column to give the title compound in a yield of 41%.
  • 1H NMR(CDCl3) δ 0.89 (t, 2H), 0.94 (d, 12H), 1.04 (t, 2H), 2.10 (m, 2H), 2.22 (d, 4H), 3.97 (d, 2H), 4.23 (s, 2H), 5.21 (s, 2H), 5.65 (m, 4H), 8.00 (s, 1H), 8.69 (s, 1H)
  • ESI: 527 (M+1)+, C23H35N4O8P
  • Example 20 Synthesis of 3-[({1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-3,7-dioxo-2,4,6-trioxa-385-phosphadec-1-yl butyrate(Compound 75)
  • The compound prepared in Example 5 was reacted with chloromethyl butyrate according to the same procedure as Example 19 at room temperature for 24 hours. The resulting product was purified by silica gel column to give the title compound in a yield of 24%.
  • 1H NMR(CDCl3) δ 0.88 (t, 2H), 0.92 (d, 6H), 1.60 (m, 4H), 2.32 (t, 4H), 3.96 (d, 2H), 4.22 (s, 2H), 5.00 (s, 2H), 5.62 (m, 4H), 8.00 (s, 1H), 8.68 (s, 1H)
  • ESI: 499 (M+1)+, C21H31N4O8P
  • Example 21 Synthesis of 3-[({1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-8-methyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl 2-methylpropanoate (Compound 78)
  • The compound prepared in Example 5 was reacted with chloromethyl isobutyrate according to the same procedure as Example 19 at room temperature for 24 hours. The resulting product was purified by silica gel column to give the title compound in a yield of 21%.
  • 1H NMR(CDCl3) δ 0.84 (t, 2H), 0.97 (t, 2H), 1.11 (d, 12H), 2.52 (m, 2H), 3.91 (d, 2H), 4.16 (s, 2H), 5.21 (s, 2H), 5.58 (m, 4H), 7.96 (s, 1H), 8.61 (s, 1H)
  • ESI: 499 (M+1)+, C21H31N4O8P
  • Example 22 Synthesis of 3-[({1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-3,7-dioxo-7-(1-pyrrolidinyl)-2,4,6-trioxa-385-phosphahept-1-yl-pyrrolidinecarboxylate (Compound 80)
  • The compound prepared in Example 5 was reacted with chloromethyl 1-pyrrolidinecarboxylate according to the same procedure as Example 19 at room temperature for 24 hours. The resulting product was purified by silica gel column to give the title compound in a yield of 35%.
  • 1H NMR(CDCl3) δ 0.82 (t, 2H), 0.87 (m, 8H), 0.98 (t, 2H), 1.57 (d, 4H), 2.26 (t, 4H), 3.91 (d, 2H), 4.16 (s, 2H), 5.12 (s, 2H), 5.57 (m, 4H), 7.98 (s, 1H), 8.62 (s, 1H)
  • ESI: 553 (M+1)+, C23H33N6O8P
  • Example 23 Synthesis of 3-[({1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-3,7-dioxo-7-(1-piperidinyl)-2,4,6-trioxa-385-phosphahept-1-yl 1-piperidinecarboxylate(Compound 81);
  • The compound prepared in Example 5 was reacted with chloromethyl 1-piperidinecarboxylate according to the same procedure as Example 19 at room temperature for 24 hours. The resulting product was purified by silica gel column to give the title compound in a yield of 39%.
  • 1H NMR(CDCl3) δ 0.86 (t, 2H), 1.02 (t, 2H), 1.47-1.58 (brm, 12H), 3.40 (brm, 8H), 3.99 (d, 2H), 4.22 (s, 2H), 5.00 (s, 2H), 5.69 (m, 4H), 8.00 (s, 1H), 8.67 (s, 1H)
  • ESI: 581 (M+1)+, C25H37N6O8P
  • Example 24 Synthesis of 3-[({1- [(2-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-7-(4-morpholinyl)-3,7-dioxo-2,4,6-trioxa-385-phosphahept-1-yl 4-morpholinecarboxylate(Compound 82)
  • The compound prepared in Example 5 was reacted with chloromethyl 4-morpholinecarboxylate according to the same procedure as Example 19 at room temperature for 24 hours. The resulting product was purified by silica gel column to give the title compound in a yield of 40%.
  • 1H NMR(CDCl3) δ 0.89 (t, 2H), 1.03 (t, 2H), 3.47 (brm, 8H), 3.65 (brm, 8H), 4.00 (d, 2H), 4.24 (s, 2H), 5.04 (s, 2H), 5.70 (m, 4H), 8.07 (s, 1H), 8.69 (s, 1H)
  • ESI: 586 (M+1)+, C23H33N6O10P
  • Example 25 Synthesis of {[1-({2-amino-6-[(4-methylphenyl)sulfanyl]-9H-purin-9-yl}methyl)cyclopropyl]oxy}methylphosphonic acid(Compound 66)
  • 6-Chloroguanine derivative prepared in Preparation 6 (4.86 g) was dissolved in 85 ml of methanol and 1.4 g of triethylamine and 2.9 g of 4-methylthiocresol were added. The reaction mixture was reacted under reflux condition for 24 hours. The reaction was stopped by adding 20 ml of water, and the methanol was removed by distillation under reduced pressure. The reaction mixture was extracted with dichloromethane and purified by silica gel column to give a compound wherein 6-position of guanine was substituted by 4-methylphenylthio group.
  • 1H NMR(CDCl3) δ 0.84 (t, 2H), 1.02 (t, 2H), 1.25-1.31 (m, 12H), 2.40 (s, 3H), 4.20 (d, 2H), 4.69 (m, 2H), 4.74 (s, 2H), 7.22 (d, 2H), 7.50 (d, 2H), 8.00 (s, 1H)
  • The compound thus obtained was reacted according to the same procedure as Example 1 and then recrystallized from a mixture of methanol-diethylether (1/20, v/v) to give the title compound.
  • 1H NMR(MeOH-d4) δ 0.98 (t, 2H), 1.06 (t, 2H), 2.42 (s, 3H), 3.92 (d, 2H), 4.48 (s, 2H), 7.35 (d, 2H), 7.55 (d, 2H), 9.05 (s, 1H)
  • ESI: 421 (M+1)+, C18H21N4O4PS
  • Example 26 Synthesis of 3-({[1-({2-amino-6-[(4-methylphenyl)sulfanyl]-9H-purin-9-yl}methyl)cyclopropyl]oxy}methyl)-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-385-phosphanon-1-yl pivalate(Compound 68)
  • The methylphosphonic acid prepared in Example 25 was reacted according to the same procedure as Example 2 to give the title compound.
  • 1H NMR(CDCl3) δ 0.82 (t, 2H), 0.98 (t, 2H), 1.18 (s, 18H), 2.36 (s, 3H), 3.93 (d, 2H), 4.15 (s, 2H), 4.93 (s, 2H), 5.60 (m, 4H), 7.18 (d, 2H), 7.48 (d, 2H), 7.88 (s, 1H)
  • ESI: 649 (M+1)+, C30H41N4O8PS
  • Example 27 Synthesis of {[1-({2-amino-6-[(4-methoxyphenyl)sulfanyl]-9H-purin-9-yl}methyl)cyclopropyl]oxy}methylphosphonic acid(Compound 96)
  • 6-Chloroguanine derivative prepared in Preparation 6 (4.86 g) was dissolved in 85 ml of methanol and 1.4 g of triethylamine and 2.9 g of 4-methoxythiocresol were added. The reaction mixture was reacted under reflux condition for 24 hours. The reaction was stopped by adding 20 ml of water, and the methanol was removed by distillation under reduced pressure. The reaction mixture was extracted with dichloromethane and purified by silica gel column to give a compound wherein 6-position of guanine was substituted by 4-methoxyphenylthio group.
  • The compound thus obtained was reacted according to the same procedure as Example 1 and then recrystallized from a mixture of methanol-diethylether (1/20, v/v) to give the title compound.
  • 1H NMR(MeOH-d4) δ 0.77 (m, 2H), 1.05 (m, 2H), 3.87 (s, 3H), 3.92 (d, 2H), 4.45 (s, 2H), 7.10 (d, 2H), 7.59 (d, 2H), 8.09 (s, 1H)
  • ESI: 438 (M+1)+, C17H20N5O5PS
  • Example 28 Synthesis of {[1-({2-amino-6-[(4-nitrophenyl)sulfanyl]-9H-purin-9-yl}methyl)cyclopropyl]oxy}methylphosphonic acid(Compound 95)
  • The compound prepared in Preparation 6 was reacted according to the same procedure as Example 27 except that 4-nitrothiocresol was used instead of 4-methoxythiocresol to give the title compound.
  • 1H NMR(MeOH-d4) δ 0.86 (m, 2H), 0.95 (m, 2H), 3.82 (d, 2H), 4.35 (s, 2H), 7.81 (d, 2H), 8.22 (d, 2H), 8.72 (s, 1H)
  • ESI: 453 (M+1)+, C16H17N6O6PS
  • Example 29 Synthesis of ({1-[(2-amino-6-hydroxy-9H-purin-9-yl)methyl]-2-methyl cyclopropyl}oxy)methylphosphonic acid(Compound 97)
  • The 6-chloroguanine derivative prepared in Preparation 12 was consecutively reacted according to the same procedure as Examples 3 and 4 to give the title compound.
  • 1H NMR(MeOH-d4) δ 0.73 (t, 1H), 1.15 (m, 1H), 1.21(d, 3H), 1.38 (t, 1H), 1.48 (m, 1H), 3.85 (t, 1H), 3.96 (t, 1H), 4.42 (d, 1H), 4.69 (d, 1H), 9.12 (s, 1H)
  • Example 30 Synthesis of {[1-({2-amino-[6-(4-methoxyphenyl)sulfanyl]-9H-purin-9-yl}methyl)-2-methylcyclopropyl]oxy}methylphosphonic acid(Compound 99)
  • The 6-chloroguanine derivative prepared in Preparation 12 was reacted according to the same procedure as Example 27 to give the title compound.
  • 1H NMR(MeOH-d4) δ 0.67 (t, 1H), 1.13 (m, 2H), 1.20 (d, 3H), 1.45 (m, 1H), 3.85 (m, 1H), 3.86 (s, 3H), 3.94 (m, 1H), 4.42 (d, 1H), 4.68 (d, 1H), 7.09 (d, 2H), 7.59 (d, 2H), 9.00 (s, 1H)
  • ESI: 452 (M+1)+, C18H22N5O5PS
  • Example 31 Synthesis of {[1-({2-amino-[6-(4-methylphenyl)sulfanyl]-9H-purin-9-yl}methyl)-2-methylcyclopropyl]oxy}methylphosphonic acid(Compound 101)
  • The 6-chloroguanine derivative prepared in Preparation 12 was reacted according to the same procedure as Example 25 to give the title compound.
  • 1H NMR(MeOH-d4) δ 0.68 (t, 1H), 1.15 (m, 2H), 1.20 (d, 3H), 1.45 (m, 1H), 2.42 (s, 3H), 3.84 (m, 1H), 3.96 (m, 1H), 4.43 (d, 1H), 4.68 (d, 1H), 7.36 (d, 2H), 7.55 (d, 2H), 9.05 (s, 1H)
  • ESI: 436 (M+1)+, C18H22N5O4PS
  • Example 32 Synthesis of {[1-({2-amino-[6-(4-nitrophenyl)sulfanyl]-9H-purin-9-yl}methyl)-2-methylcyclopropyl]oxy}methylphosphonic acid(Compound 100)
  • The 6-chloroguanine derivative prepared in Preparation 12 was reacted according to the same procedure as Example 28 to give the title compound.
  • 1H NMR(MeOH-d4) δ 0.49 (t, 1H), 0.93 (m, 1H), 1.00 (d, 3H), 1.25 (m, 1H), 3.64 (m, 1H), 3.76 (m, 1H), 4.28 (d, 1H), 4.53 (d, 1H), 7.72 (d, 2H), 8.14 (d, 2H), 9.10 (s, 1H)
  • ESI: 467 (M+1)+, C17H19N6O6PS
  • Example 33 Synthesis of ({1-[(6-amino-9H-purin-9-yl)methyl]-2-methylcyclopropyl}oxy)methylphosphonic acid(Compound 103)
  • The adenine derivative prepared in Preparation 11 was reacted according to the same procedure as Example 1 to give the title compound.
  • 1H NMR(MeOH-d4) δ 0.64 (t, 1H), 1.09 (m, 1H), 1.20 (d, 3H), 1.43 (m, 1H), 3.83 (m, 1H), 3.95 (m, 1H), 4.49 (d, 1H), 4.75 (d, 1H), 5.49 (s, 2H), 8.39 (s, 1H), 8.55 (s, 1H)
  • ESI: 314 (M+1)+, C11H16N5O4P
  • Example 34 Synthesis of bis{[(t-butoxycarbonyl)oxy]methyl}({1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methylphosphonate(Compound 69)
  • The compound prepared in Example 5 (187 mg) was mixed with 6 ml of N-methyl-2-pyrrolidone, and 300 mg of triethylamine and 150 mg of chloromethyl t-butylcarbonate were added. The reaction solution was stirred at room temperature for 4 hours. The reaction was stopped by adding 10 ml of water, and the reaction mixture was extracted with ethyl acetate. The extract was distilled under reduced pressure and purified by silica gel column to give the title compound.
  • 1H NMR(CDCl3) δ 0.86 (m, 2H), 1.06 (m, 2H), 1.47 (s, 18H), 4.01 (d, 4H), 4.22 (s, 2H), 5.00 (brs, 2H), 5.61 (m, 4H), 7.99 (s, 1H), 8.69 (s, 1H)
  • ESI: 344 (M+1)+, C22H34N5O10P
  • Example 35 Synthesis of bis{[(isopropoxycarbonyl)oxy]methyl}({1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methylphosphonate(Compound 70)
  • The compound prepared in Example 5 (100 mg) was mixed with 5 ml of N-methyl-2-pyrrolidone, and 110 mg of triethylamine and 150 mg of chloromethyl isopropylcarbonate were added. The reaction solution was stirred at 50 for 4 hours. The reaction was stopped by adding 10 ml of water, and the reaction mixture was extracted with ethyl acetate. The extract was distilled under reduced pressure and purified by silica gel column to give the title compound.
  • 1H NMR(CDCl3) δ 0.88 (s, 2H), 1.06 (s, 2H), 1.29 (d, 2H), 1.31 (d, 2H), 4.01 (d, 4H), 4.21 (s, 2H), 4.92 (m, 2H), 5.01 (brs, 2H), 5.64 (m, 4H), 7.99 (s, 1H), 8.69 (s, 1H)
  • ESI: 532 (M+1)+, C20H30N5O10P
  • Example 36 Synthesis of ({1-[(2-amino-6-hydroxy-9H-purin-9-yl)methyl]-2,2-dimethyl cyclopropyl}oxy)methylphosphonic acid(Compound 146)
  • The compound prepared in Preparation 32 was consecutively reacted according to the same procedure as Examples 1 and 4 to give the title compound.
  • 1H NMR(MeOH-d4) δ 0.78 (d, 1H), 0.82 (d, 1H), 1.21 (s, 3H), 1.27 (s, 3H), 3.90 (d, 1H), 3.91 (d, 1H), 4.58 (s, 2H), 9.12 (s, 1H)
  • ESI: 344 (M+1)+, C12H18N5O5P
  • Example 37 Synthesis of ({1-[(2-amino-9H-purin-9-yl)methyl]-2,2-dimethylcyclopropyl}oxy)methylphosphonic acid(Compound 147)
  • The compound prepared in Preparation 32 was reacted according to the same procedure as Example 5 to give a compound wherein 6-position of guanine was reduced by hydrogen.
  • 1H NMR(CDCl3) δ 0.60 (d, 1H), 0.82 (d, 1H), 1.21 (s, 3H), 1.22 (s, 3H), 1.22 (m, 15H), 3.73 (m, 1H), 3.87 (m, 1H), 4.13 (d, 1H), 4.49 (d, 1H), 4.67 (m, 2H), 4.98 (brs, 2H), 8.09 (s, 1H), 9.67 (s, 1H)
  • The compound thus obtained was reacted according to the same procedure as Example 1 to give the title compound.
  • 1H NMR(MeOH-d4) δ 0.74 (d, 1H), 0.81 (d, 1H), 1.21 (s, 3H), 1.26 (s, 3H), 3.91 (d, 2H), 4.49 (d, 1H), 4.57 (d, 1H), 8.63 (s, 1H), 8.74 (s, 1H)
  • ESI: 328 (M+1)+, C12H18N5O4P
  • Example 38 Synthesis of ({1-[(6-amino-9H-purin-9-yl)methyl]-2,2-dimethylcyclopropyl}oxy)methylphosphonic acid(Compound 148)
  • The compound prepared in Preparation 31 was reacted according to the same procedure as Example 1 to give the title compound.
  • 1H NMR(MeOH-d4) δ 0.77 (d, 1H), 0.79 (d, 1H), 1.25 (s, 3H), 1.28 (s, 3H), 3.90 (d, 2H), 4.61 (d, 1H), 4.70 (d, 1H), 8.38 (s, 1H), 8.51 (s, 1H)
  • ESI: 328 (M+1)+, C12H18N5O4P
  • Example 39 Synthesis of (E)-2-{1-[(2-amino-6-hydroxy-9H-purin-9-yl)methyl]cyclopropyl}ethenylphosphonic acid(Compound 130)
  • The compound prepared in Preparation 26 was reacted according to the same procedure as Example 1 to give phosphonic acid derivative.
  • 1H NMR(MeOH-d4) δ 1.07 (t, 2H), 1.33 (t, 1H), 4.41 (s, 2H), 5.76 (dd, 1H), 6.45 (dd, 1H), 9.18 (s, 1H)
  • The compound thus obtained was reacted according to the same procedure as Example 4 to give the title compound.
  • 1H NMR(MeOH-d4) δ 1.08 (t, 2H), 1.34 (t, 1H), 4.38 (s, 2H), 5.78 (dd, 1H), 6.46 (dd, 1H), 9.11 (s, 1H)
  • ESI: 312 (M+1)+, C11H14N5O4P
  • Example 40 Synthesis of 2-{1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}ethyl phosphonic acid(Compound 139)
  • The compound prepared in Preparation 26 was reacted according to the same procedure as Example 5 to give the title compound.
  • 1H NMR(MeOH-d4) δ 0.58 (t, 2H), 0.85 (t, 2H), 1.42 (m, 2H), 1.95 (m, 2H), 4.11 (s, 2H), 5.78 (dd, 1H), 8.55 (s, 1H), 8.75(s, 1H)
  • ESI: 298 (M+1)+, C11H16N5O3P
  • Example 41 Synthesis of (E)-2-{1-[(6-amino-9H-purin-9-yl)methyl]cyclopropyl}ethenyl phosphonic acid(Compound 132)
  • The compound prepared in Preparation 25 was reacted according to the same procedure as Example 1 to give the title compound.
  • 1H NMR(MeOH-d4) δ 0.94 (t, 2H), 1.20 (t, 2H), 4.36 (s, 2H), 5.63 (dd, 1H), 6.37 (dd, 1H), 8.30 (s, 1H), 8.31 (s, 1H)
  • ESI: 296 (M+1)+, C11H14N5O3P
  • Example 42 Synthesis of 2-{1-[(6-amino-9H-purin-9-yl)methyl]cyclopropyl}ethyl phosphonic acid(Compound 140)
  • The compound prepared in Preparation 25 was reacted according to the same procedure as Example 5 to give the title compound.
  • 1H NMR(MeOH-d4) δ 0.58 (t, 2H), 0.87 (t, 2H), 1.37 (m, 2H), 1.97 (m, 2H), 4.24 (s, 2H), 8.31 (s, 1H), 8.42 (s, 1H)
  • ESI: 298 (M+1)+, C11H16N5O3P
  • Example 43 Synthesis of 2-{1-[(2-amino-6-hydroxy-9H-purin-9-yl)methyl]cyclopropyl}ethylphosphonic acid(Compound 138)
  • The compound prepared in Preparation 26 was reacted according to the same procedure as Example 12 to give a compound wherein 6-position of guanine was substituted by ethoxy group.
  • 1H NMR(CDCl3) δ 1.00 (t, 2H), 1.10 (t, 2H), 1.16-1.21 (m, 9H), 3.90 (m, 4H), 4.01 (m, 2H), 4.13 (s, 2H), 4.92 (s, 2H), 5.58 (dd, 1H), 6.49 (dd, 1H), 7.62 (s, 1H)
  • The compound thus obtained (80 mg) was dissolved in methanol and reacted under hydrogen atrmosphere in the presence of 20 mg of 10% Pd/C to give a compound wherein double bond was reduced.
  • 1H NMR(CDCl3) δ 0.49 (t, 2H), 0.66 (t, 2H), 1.21 (t, 6H), 1.42 (m, 2H), 2.01 (m, 2H), 3.99 (m, 6H), 4.96 (s, 2H), 7.59 (s, 1H)
  • The compound thus obtained was reacted according to the same procedure as Example 1 to give the title compound.
  • 1H NMR(MeOH-d4) δ 0.60 (t, 2H), 0.87 (t, 2H), 1.47 (m, 2H), 1.97 (m, 2H), 4.16 (s, 2H), 9.12 (s, 1H)
  • ESI: 314 (M+1)+, C11H16N5O4P
  • Example 44 Synthesis of 2-{1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}propyl phosphonic acid(Compound 144)
  • The compound prepared in Preparation 35 was consecutively reacted according to the same procedure as Preparations 24, 26 and Example 5 to give the title compound.
  • 1H NMR(MeOH-d4) δ 0.62-0.77 (m, 4H), 1.04 (d, 3H), 1.52 (m, 2H), 1.90 (m, 1H), 4.24 (m, 2H), 8.58 (s, 1H), 8.74 (s, 1H)
  • ESI: 312 (M+1)+, C12H18N5O3P
  • Example 45 Synthesis of (E)-2-{1-[(6-amino-9H-purin-9-yl)methyl]cyclopropyl}-1-propenylphosphonic acid(Compound 137)
  • The compound prepared in Preparation 35 was consecutively reacted according to the same procedure as Preparations 24, 25 and Example 1 to give the title compound.
  • 1H NMR(MeOH-d4) δ 0.86 (t, 2H), 1.10 (t, 2H), 2.19 (d, 3H), 4.38 (s, 2H), 5.23 (d, 1H), 8.34 (s, 1H), 8.37(s, 1H)
  • ESI: 310 (M+1)+, C12H16N5O3P
  • Example 46 Synthesis of 2-{1-[(6-amino-9H-purin-9-yl)methyl]cyclopropyl}propyl phosphonic acid(Compound 143)
  • The compound prepared in Preparation 35 was consecutively reacted according to the same procedure as Preparations 24, 25 and Example 5 to give the title compound.
  • 1H NMR(MeOH-d4) δ 0.65 (t, 2H), 0.78 (t, 2H), 0.95 (m, 1H), 1.00 (d, 3H), 1.53 (s, 1H), 1.90 (m, 1H), 4.3 (q, 2H), 8.41 (s, 1H), 8.45 (s, 1H)
  • ESI: 312 (M+1)+, C12H18N5O3P
  • Example 47 Synthesis of bis(2,2,2-trifluoroethyl)({1-[(6-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methylphosphonate(Compound 48)
  • To the methylphosphonic acid prepared in Example 1 (150 mg) was added dropwise dichloromethane, 0.73 ml of N,N-diethyltrimethylsilylamine was added dropwise thereto, and the resulting mixture was stirred at room temperature for 2 hours. Oxalyl chloride (0.15 ml) and 2 drops of dimethylformamide were added to the reaction vessel. The mixture was stirred for further 2 hours and the solvent was removed by distillation under reduced pressure. To the residue were added 10 ml of pyridine and 2 ml of trifluoroethanol, which was then reacted under stirring for 16 hours. The solvent was removed by distillation under reduced pressure and the residue was purified by silica gel column to give the title compound.
  • 1H NMR(CD3OD) δ 1.02 (m, 4H), 4.30 (d, 2H), 4.53 (m, 6H), 8.40 (s, 1H), 8.46(s, 1H)
  • ESI: 464 [M+H]+: C14H16F6N5O4P
  • Example 48 Synthesis of bis(2,2,2-trifluoroethyl)({1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methylphosphonate(Compound 49)
  • The compound prepared in Example 5 was reacted according to the same procedure as Example 47 to give the title compound.
  • 1H NMR(CDCl3) δ 0.88 (m, 2H), 1.04 (m, 2H), 4.07 (d, 2H), 4.22 (s, 2H), 4.33 (m, 4H), 5.06 (br.s, 2H), 7.92 (s, 1H), 8.68 (s, 1H)
  • ESI: 464 [M+H]+, C14H16F6N5O4P
  • Example 49 Synthesis of bis(2,2,2-trifluoroethyl)[1-({2-amino-[6-(4-methylphenyl)sulfanyl]-9H-purin-9-yl}methyl)cyclopropyl]oxy}methylphosphonate(Compound 62)
  • The compound prepared in Example 25 was reacted according to the same procedure as Example 47 to give the title compound.
  • 1H NMR(CDCl3) δ 0.88 (m, 2H), 1.03 (m, 2H), 2.39 (s, 3H), 4.06 (d, 2H), 4.19 (s, 2H), 4.33 (m, 4H), 4.76 (br.s, 2H), 7.22 (d, 2H), 7.50 (d, 2H), 7.82 (s, 1H)
  • ESI: 586 [M+H]+, C21H22F6N5O4PS
  • Example 50 Synthesis of bis(2,2,2-trifluoroethyl)[(1-{[2-amino-6-hydroxy-9H-purin-9-yl]methyl}cyclopropyl)oxy]methylphosphonate(Compound 45)
  • The compound prepared in Example 4 was reacted according to the same procedure as Example 47 to give the title compound.
  • 1H NMR(CDCl3) δ 0.91 (m, 2H), 1.05 (m, 2H), 4.08 (d, 2H), 4.17 (s, 2H), 4.35 (m, 4H), 4.70 (s, 2H), 7.69 (s, 1H)
  • MW=478 [M+H]+479 C14H16F6N5O5P
  • Example 51 Synthesis of bis(2,2,2-trifluoroethyl)(1-{[2-amino-6-cyclopropylamino-9H-purin-9-yl]methyl}cyclopropyl)oxy]methylphosphonate(Compound 50)
  • The compound prepared in Example 7 was reacted according to the same procedure as Example 47 to give the title compound.
  • 1H NMR(CDCl3) δ 0.60 (br.s, 2H), 0.84 (br.s, 4H), 1.01 (m, 2H), 2.98 (br.s, 1H), 4.05 (d, 2H), 4.14 (m, 4H), 4.70 (br.s, 2H), 5.67 (br.s, 1H), 7.60 (s, 1H)
  • ESI: 519, [M+H]+, C17H21F6N6O4P
  • Example 52 Synthesis of ({1-[(2-amino-9H-purin-9-yl)methyl]-2-methylcyclopropyl}oxy)methylphosphonic acid(Compound 98)
  • The 6-chloroguanine derivative prepared in Preparation 12 was reacted according to the same procedure as Example 5 to give the title compound.
  • 1H NMR(MeOH-d4) δ 0.68 (t, 1H), 1.13 (m, 1H), 1.21 (d, 3H), 1.42 (t, 1H), 3.84 (t, 1H), 3.97 (t, 1H), 4.40 (d, 1H), 4.66 (d, 1H), 8.63 (s, 1H), 8.73 (s, 1H)
  • ESI: 314 (M+1)+, C11H16N5O4P
  • The compound of the present invention exhibits a potent pharmacological effect to a hepatitis B cell line, HepG2.2.15, and a transgenic mouse, widely used for development of a therapeutic agent against hepatitis B, when intravenously or orally administered. The experimental procedures and results are described below.
  • Experiment 1
  • Measurement and Analysis of Inhibition Effect against Hepatitis B Virus (HBV)
  • (1) Cell Culture and Treatment with Drugs
  • HepG2.2.15 cell (M. A Shells et al., P.N.A.S. 84, 1005(1987)), a hepatocarcinoma cell line producing hepatitis B virus, was cultured in DMEM medium(GIBCO BRL, #430-2200) containing 10% FBS(Fetus bovine serum, GIBCO BRL, #16000-044), 1% ABAM (Antibiotic-Antimycotic, GIBCO BRL, #16000-028) and 400 μg/ml of geneticin(Sigma, #G-9516) in a T-75 flask under the conditions of 5% CO2 incubator and 37° C. by dividing in a ratio of 1:3 at an interval of 3 days. The cells were distributed into a 96-well plate in the amount of 4×104/well and then when 80-90% of cell density was achieved, the old medium was changed with 200 μl of DMEM medium containing 2% FBS, 1% ABAM and 400 μg/ml of geneticin. The drug solution was sequentially diluted five-fold each time, from 100 M to 0.16 M. In order to minimize an experimental error, each treatment was repeated 2-3 times for the respective drugs. The medium was changed every two days. On 10 days after the treatment with drug, 100 μl of the medium was collected and the degree of inhibition of viral replication by drugs was determined through quantitative PCR (Polymerase Chain Reaction).
  • (2) Determination of Cytotoxicity
  • After 100 μl of the medium was collected on 10th day from the treatment with drug, 7.5 mg/ml of MTT (Thiazolyl Blue Tetrazolium Broide, Amresco, #0793-5G) solution was added to each well in the amount of 30 μl/well and each cell was cultured for 2 hours in a 5% CO2incubator at 37° C. The solution was discarded, and an isopropanol solution containing 10% Triton X-100 and 0.4 μl of c-HCl was added to each well in the amount of 120 μl/well. The cells thus dyed were transferred to the isopropanol solution by shaking for 2 hours. Absorbance at 540 nm was measured by Elisa Reader.
  • (3) PCR Estimation of Inhibition Effect on Hepatitis B Virus Replication
  • The degree of inhibition by drugs on the replication of hepatitis B virus was determined using the cell culture solution collected on 10th day after the treatment with the drug. The cell culture solution treated with each drug was diluted ten-fold with distilled water and subjected to a pretreatment to destroy the cells by heating them for 15 minutes at 95° C. For the PCR amplification of the gene fragment of about 320 bp, the 2001-base position that is conserved in all sub-strain of hepatitis B virus and 2319-base position that is between the core antigen gene and polymerase gene were used as 5′-end and 3′-end primer, respectively. Then, the amount of genomic DNA of hepatitis B virus was quantified, and the inhibitory effect by drugs on the replication of hepatitis B virus was determined on the basis thereof.
  • First, the cell culture solution of hepatitis B virus that was not treated with drug was sequentially diluted and amplified through the PCR. The amplified DNA was subjected to electrophoresis on 2% agarose gel and stained with ethidium bromide (EtBr) to be analyzed by IS-1000 (Innotech Scientific Corporation) Digital Imaging System. Analysis of the cell culture solution treated with drug was then carried out using the dilution fold in the range where linearity is maintained. The DNA obtained from the group treated with drug was amplified through the same PCR method, subjected to electrophoresis on 2% agarose gel, stained with ethidium bromide, and analyzed by IS-1000. The degree of inhibition by drugs in the viral replication was quantified by calculating the ratio of test group to control group. Table 8 summarizes the inhibitory effect (pharmaceutical activity and toxicity) of the typical compounds of the present invention.
  • TABLE 8
    COM. NO. EC50 (μM) in HBV
    PMEA 5.0
    (Comparative Compound)
     1 >1.0
     3 >0.5
     5 >0.1
    10 >0.08
    95 >0.5
    97 >0.05
  • As can be seen from the results of Table 8, the compound according to the present invention exhibits 4 to 10-fold greater activity than the comparative compound PMEA that is on Phase III in clinical trials.
  • Experiment 2
  • Pharmacological Test on Transgenic Mouse (T/G Mouse)
  • The compounds were administered via subcutaneous and oral routes in the following animal test.
  • The test compounds were administered to 4-5 weeks old HBV transgenic mice, which were obtained from FVB strain mice according to a method described in a reference (see, Jone D. Morrey, Kevin W. Bailey, Brent E. Korba, Robert W. Sidwell, “Utilization of transgenic mice replicating high levels of hepatitis B virus for antiviral evaluation of lamivudine” Antiviral research, 1999, 42, 97-108), subcutaneously for 9 days in the amount of 10 mg/kg/day and orally for 9 days in the amount of 10, 2 and 0.4 mg/kg/day, once a day, respectively (the same number of males and females were used). Blood was collected from the tail of the mouse and 5 μl of serum was obtained. To this serum was added 15 ml of Genereleaser sol, which was then pretreated in different temperatures. HBV DNA was taken from the pretreated solution. The DNA was amplified by the PCR (Polymerase Chain Reaction) in the presence of 4 μl of 10×buffer (Perkin Elmer), 0.8 μl of 10 mM dNTP, 500 ng of the same HBV primers as used in Experiment 1, 2,125 mM of MgCl2, DMSO and Taq polymerase. The amount of HBV DNA was analyzed by electrophoresis in order to evaluate a pharmacological effect of the compound of the present invention. The results are described in the following Table 9. In the following Table 9, ┌mice showing pharmacological effect┘ means the mice whose blood does not contain HBV DNA.
  • TABLE 9
    Amount
    COM. NO. (mg/kg/day) Result* Administration
    23 10 4/4 subcutaneous
    66 10 4/4 subcutaneous
    97 10 4/4 subcutaneous
    95 10 3/4 subcutaneous
    98 10 4/4 subcutaneous
    PMEA dipivoxil 2 1/3 oral
    PMEA dipivoxil 0.4 1/6 oral
    10 2 4/4 oral
    10 0.4 5/6 oral
    *The result means ┌number of mice showing pharmacological effect/number of total mice┘
  • As can be seen in the above Table 9, the compound of the present invention shows a potent hepatitis B therapeutic effect in the tested animals when orally or subcutaneously administered. Particularly, since the compound of the present invention is superior to the comparative compound PMEA, which is on Phase III in clinical trials, it is expected that the compound of the present invention may be used very effectively for the treatment of hepatitis B.

Claims (1)

1. A phosphonate compound represented by the following formula (2):
Figure US20100004440A1-20100107-C00240
in which
Figure US20100004440A1-20100107-P00001
represents single bond or double bond,
R1, R2, R3, R7, and R8 independently of one another represent hydrogen, halogen, hydroxyl, amino, C1-C7-alkyl, C2-C6-alkenyl, C1-C5-alkylamino, C1-C5-aminoalkyl, or C1-C5-alkoxy,
R4 and R5 independently of one another represent hydrogen, or represent C1-C4-alkyl optionally substituted by one or more substituents selected from the group consisting of halogen, C1-C4-alkoxy, phenoxy, C7-C10-phenylalkoxy and C2-C5-acyloxy, wherein C2-C5-acyloxy is RC(O)O— and R is C2-C5-alkyl, or represent C1-C7-acyl, wherein C1-C7-acyl is RC(O)— and R is C1-C7-alkyl, C6-C12-aryl or optionally substituted carbamoyl, or represent —(CH2)m-OC(═O)—R6 wherein m denotes an integer of 1 to 12 and R6 represents C1-C12-alkyl, C2-C7-alkenyl, C1-C5-alkoxy, C1-C7-alkylamino, di(C1-C7-alkyl)amino, C3-C6-cycloalkyl, or 3 to 6-membered heterocycle having 1 or 2 hetero atoms selected from a group consisting of nitrogen and oxygen,
Y represents —O—, —S—, —CH(Z)-, ═C(Z)-, —N(Z)-, ═N—, —SiH(Z)-, or =Si(Z)-, wherein Z represents hydrogen, hydroxyl or halogen, or represents C1-C7-alkyl, C1-C5-alkoxy, allyl, hydroxy-C1-C7-alkyl, C1-C7-aminoalkyl or phenyl, and
L represents a leaving group.
US12/585,229 2001-01-19 2009-09-09 Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same Expired - Fee Related US7723319B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/585,229 US7723319B2 (en) 2001-01-19 2009-09-09 Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
KR20010003087 2001-01-19
KR2001-3087 2001-01-19
US10/450,780 US7157448B2 (en) 2001-01-19 2002-01-18 Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same
PCT/KR2002/000086 WO2002057288A1 (en) 2001-01-19 2002-01-18 Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same
US11/455,679 US7605147B2 (en) 2001-01-19 2006-06-20 Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same
US12/585,229 US7723319B2 (en) 2001-01-19 2009-09-09 Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/455,679 Division US7605147B2 (en) 2001-01-19 2006-06-20 Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same

Publications (2)

Publication Number Publication Date
US20100004440A1 true US20100004440A1 (en) 2010-01-07
US7723319B2 US7723319B2 (en) 2010-05-25

Family

ID=36241797

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/450,780 Expired - Fee Related US7157448B2 (en) 2001-01-19 2002-01-18 Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same
US11/455,679 Expired - Fee Related US7605147B2 (en) 2001-01-19 2006-06-20 Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same
US12/585,229 Expired - Fee Related US7723319B2 (en) 2001-01-19 2009-09-09 Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US10/450,780 Expired - Fee Related US7157448B2 (en) 2001-01-19 2002-01-18 Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same
US11/455,679 Expired - Fee Related US7605147B2 (en) 2001-01-19 2006-06-20 Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same

Country Status (23)

Country Link
US (3) US7157448B2 (en)
EP (1) EP1358198B1 (en)
JP (1) JP3959348B2 (en)
KR (1) KR100441638B1 (en)
CN (1) CN100347185C (en)
AR (1) AR035933A1 (en)
AT (1) ATE478887T1 (en)
AU (1) AU2002230230B2 (en)
BR (1) BR0206165A (en)
CA (1) CA2433591C (en)
DE (1) DE60237429D1 (en)
DK (1) DK1358198T3 (en)
EG (1) EG24382A (en)
ES (1) ES2350197T3 (en)
HK (1) HK1062017A1 (en)
MX (1) MXPA03006001A (en)
MY (1) MY141789A (en)
NZ (1) NZ526632A (en)
PL (1) PL212730B1 (en)
PT (1) PT1358198E (en)
RU (1) RU2266294C2 (en)
WO (1) WO2002057288A1 (en)
ZA (1) ZA200304181B (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY141789A (en) * 2001-01-19 2010-06-30 Lg Chem Investment Ltd Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same.
AU2002252179A1 (en) * 2001-03-01 2002-09-19 Conforma Therapeutics Corp. Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
AU2002343604C1 (en) 2001-10-30 2009-09-17 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
RU2005108601A (en) * 2002-09-26 2006-01-20 Эл Джи Лайф Сайенсиз Лтд. (Kr) (+) - TRANS-ISOMERS (1-PHOSPHONOMETOXY-2-ALKYL CYCLOPROPYL) METHYL NUCLEOSIDE DERIVATIVES, METHOD FOR PRODUCING THEIR STEREOISOMERS AND APPLICATION OF THESE COMPOUNDS AS A RELATED TO
CA2539548A1 (en) 2003-09-18 2005-03-31 Conforma Therapeutics Corporation Novel heterocyclic compounds as hsp90-inhibitors
KR20050062940A (en) * 2003-12-19 2005-06-28 주식회사 엘지생명과학 New process for preparing diisopropyl ((1-((2-amino-6-halo-9h-purin-9-yl)methyl)cyclopropyl)oxy)-methylphosphonate
KR20050062944A (en) * 2003-12-19 2005-06-28 주식회사 엘지생명과학 New process for preparing diisopropyl ((1-((2-amino-6-chloro-9h-purin-9-yl)methyl)cyclopropyl)oxy)-methylphosphonate
CA2555213C (en) * 2004-02-17 2009-12-01 Devron R. Averett Nucleoside phosphonate derivatives useful in the treatment of hiv infections
KR101033290B1 (en) 2004-07-02 2011-05-09 주식회사 엘지생명과학 New process for preparing diisopropyl 1-hydroxymethyl-cyclopropyloxymethylphosphonate
WO2006066074A2 (en) 2004-12-16 2006-06-22 The Regents Of The University Of California Lung-targeted drugs
EP1869027A4 (en) 2005-03-30 2010-06-23 Conforma Therapeutics Corp Alkynyl pyrrolopyrimidines and related analogs as hsp90-inhibitors
CN104110609B (en) * 2006-02-27 2017-03-01 照明管理解决方案公司 A kind of improved LED matrix producing angle pencil of ray
US8434912B2 (en) * 2006-02-27 2013-05-07 Illumination Management Solutions, Inc. LED device for wide beam generation
GB0623493D0 (en) * 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
TWI384986B (en) * 2007-01-17 2013-02-11 Lg Life Sciences Ltd Maleic acid monosalt of antiviral agent and pharmaceutical composition containing the same
WO2009023299A2 (en) 2007-04-13 2009-02-19 Southern Research Institute Anti-angiogenic agents and methods of use
CN101687473B (en) * 2007-05-21 2014-12-03 照明管理解决方案有限公司 An improved led device for wide beam generation and method of making the same
BRPI0918716A2 (en) * 2008-08-14 2015-12-01 Cooper Technologies Co LED devices for wide beam offset generation
WO2010065663A2 (en) * 2008-12-03 2010-06-10 Illumination Management Solutions, Inc. An led replacement lamp and a method of replacing preexisting luminaires with led lighting assemblies
CN102093422B (en) * 2009-12-10 2015-02-25 中国人民解放军军事医学科学院毒物药物研究所 Acyclic nucleoside phosphonate derivative and medicinal application thereof
CN102286026B (en) * 2010-06-18 2014-07-02 中国人民解放军军事医学科学院毒物药物研究所 Acyclic nucleotide analogue, crystal form and medicinal composition thereof
NZ611438A (en) 2010-12-10 2015-06-26 Sigmapharm Lab Llc Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs
CN107312039B (en) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 A kind of preparation method of tenofovir prodrug
PT2970346T (en) 2013-03-15 2018-11-09 Univ California Acyclic nucleoside phosphonate diesters
CN104119385B (en) * 2014-07-24 2017-04-05 廖国超 The phosphate prodrugs of nucleoside analog and its application
RS63250B1 (en) 2014-09-15 2022-06-30 Univ California Nucleotide analogs
CN106432330B (en) * 2015-08-11 2019-02-01 天津科伦药物研究有限公司 The midbody compound and its preparation method and application of LB80380 drug
EP3875462A1 (en) 2015-09-15 2021-09-08 The Regents of The University of California Nucleotide analogs
CN106977548A (en) * 2016-01-19 2017-07-25 四川海思科制药有限公司 Times Si Fuwei compounds and its production and use
CN107849074A (en) * 2016-01-19 2018-03-27 四川海思科制药有限公司 A kind of alkoxyalkyl ester prodrugs of nucleoside analog and its application
KR102623581B1 (en) * 2016-07-18 2024-01-11 일동제약(주) Orotic acid salt of antiviral agent, a method for preparing the salt and pharmaceutical composition comprising the salt
CN108276443A (en) * 2017-01-06 2018-07-13 米文君 A kind of new compound and application thereof
KR102096144B1 (en) * 2017-07-03 2020-04-01 주식회사 엘지화학 Continuous production method of intermediate compounds used for synthesizing phosphonate nucleosides based compounds as therapeutic agents for hepatitis b
CN108997429B (en) * 2018-07-27 2020-10-30 广州粤美医药科技有限公司 Method for preparing Beciclovir
CN113735863A (en) * 2021-09-29 2021-12-03 武汉九州钰民医药科技有限公司 Preparation process of Wee1 inhibitor avaposertib
CN113880883A (en) * 2021-11-11 2022-01-04 奥锐特药业股份有限公司 Nucleoside phosphate prodrug preparation method
CN114560463B (en) * 2022-03-23 2023-10-20 福州大学 Preparation method of nitrogen-doped carbon-shell-coated molybdenum carbide core microsphere material with core-shell structure

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039654A (en) * 1974-08-08 1977-08-02 Imperial Chemical Industries Limited Prostanoic acid derivatives
US5663159A (en) * 1990-09-14 1997-09-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
US5688778A (en) * 1989-05-15 1997-11-18 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Nucleoside analogs
US5817647A (en) * 1993-04-01 1998-10-06 Merrell Pharmaceuticals Inc. Unsaturated acetylene phosphonate derivatives of purines
US5877166A (en) * 1996-04-29 1999-03-02 Sri International Enantiomerically pure 2-aminopurine phosphonate nucleotide analogs as antiviral agents
US5886179A (en) * 1993-09-17 1999-03-23 Gilead Sciences, Inc. Nucleotide analogs
US5935946A (en) * 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
US5977061A (en) * 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
US6037335A (en) * 1993-06-29 2000-03-14 Mitsubishi Chemical Corporation Phosphonate-nucleotide ester derivatives
US6069249A (en) * 1996-07-26 2000-05-30 Gilead Sciences, Inc. Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
US20050124582A1 (en) * 2002-03-15 2005-06-09 Jiri Zemlicka 2-amino-9-[(2-hydroxymethyl) cyclopropylidenemethyl] purine antiviral agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8922076D0 (en) * 1989-09-28 1989-11-15 Beecham Group Plc Novel process
US5177104A (en) 1990-04-03 1993-01-05 E. R. Squibb & Sons, Inc. 6-α-hydroxy derivatives of mevinic acids
US5302585A (en) * 1990-04-20 1994-04-12 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
ES2085446T3 (en) * 1990-07-04 1996-06-01 Merrell Pharma Inc DERIVATIVES OF 9-PURINYL PHOSPHONIC ACID.
DK0502690T3 (en) * 1991-03-05 2000-05-22 Ajinomoto Kk cyclopropane derivative
WO1995022330A1 (en) 1994-02-17 1995-08-24 Commonwealth Scientific And Industrial Research Organisation Antiviral agents
IT1270008B (en) 1994-09-23 1997-04-16 Ist Superiore Sanita PURINIC AND 8-AZAPURINIC DERIVATIVES FOR THE THERAPEUTIC TREATMENT OF AIDS
US5874577A (en) * 1996-04-03 1999-02-23 Medichem Research, Inc. Method for the preparing 9-12-(Diethoxyphosphonomethoxy)ethyl!adenine and analogues thereof
DK0988304T3 (en) 1997-08-15 2001-08-20 Medivir Ab Nucleoside analogues such as antivirals comprising inhibitors of retroviral reverse transcriptase and the hepatitis B virus (HBV) DNA polymerase
MY141789A (en) 2001-01-19 2010-06-30 Lg Chem Investment Ltd Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same.
RU2005108601A (en) * 2002-09-26 2006-01-20 Эл Джи Лайф Сайенсиз Лтд. (Kr) (+) - TRANS-ISOMERS (1-PHOSPHONOMETOXY-2-ALKYL CYCLOPROPYL) METHYL NUCLEOSIDE DERIVATIVES, METHOD FOR PRODUCING THEIR STEREOISOMERS AND APPLICATION OF THESE COMPOUNDS AS A RELATED TO

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039654A (en) * 1974-08-08 1977-08-02 Imperial Chemical Industries Limited Prostanoic acid derivatives
US5688778A (en) * 1989-05-15 1997-11-18 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Nucleoside analogs
US5693798A (en) * 1989-05-15 1997-12-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Phosphonate nucleoside analogs
US5837871A (en) * 1989-05-15 1998-11-17 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Nucleoside analogs
US5663159A (en) * 1990-09-14 1997-09-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
US5817647A (en) * 1993-04-01 1998-10-06 Merrell Pharmaceuticals Inc. Unsaturated acetylene phosphonate derivatives of purines
US6037335A (en) * 1993-06-29 2000-03-14 Mitsubishi Chemical Corporation Phosphonate-nucleotide ester derivatives
US5886179A (en) * 1993-09-17 1999-03-23 Gilead Sciences, Inc. Nucleotide analogs
US5977061A (en) * 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
US5877166A (en) * 1996-04-29 1999-03-02 Sri International Enantiomerically pure 2-aminopurine phosphonate nucleotide analogs as antiviral agents
US6069249A (en) * 1996-07-26 2000-05-30 Gilead Sciences, Inc. Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
US5935946A (en) * 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
US20050124582A1 (en) * 2002-03-15 2005-06-09 Jiri Zemlicka 2-amino-9-[(2-hydroxymethyl) cyclopropylidenemethyl] purine antiviral agents

Also Published As

Publication number Publication date
KR20020062216A (en) 2002-07-25
PT1358198E (en) 2010-10-01
MY141789A (en) 2010-06-30
EP1358198A1 (en) 2003-11-05
BR0206165A (en) 2004-02-03
AR035933A1 (en) 2004-07-28
PL212730B1 (en) 2012-11-30
MXPA03006001A (en) 2003-09-10
DE60237429D1 (en) 2010-10-07
WO2002057288A1 (en) 2002-07-25
AU2002230230B2 (en) 2005-05-26
ATE478887T1 (en) 2010-09-15
DK1358198T3 (en) 2010-10-04
CA2433591C (en) 2009-07-28
EG24382A (en) 2009-04-05
HK1062017A1 (en) 2004-10-15
NZ526632A (en) 2005-10-28
KR100441638B1 (en) 2004-07-23
CN100347185C (en) 2007-11-07
ZA200304181B (en) 2004-10-06
US7157448B2 (en) 2007-01-02
CA2433591A1 (en) 2002-07-25
ES2350197T3 (en) 2011-01-20
EP1358198B1 (en) 2010-08-25
JP2004518675A (en) 2004-06-24
US7605147B2 (en) 2009-10-20
CN1487949A (en) 2004-04-07
US7723319B2 (en) 2010-05-25
RU2003125372A (en) 2005-01-20
US20040063668A1 (en) 2004-04-01
RU2266294C2 (en) 2005-12-20
EP1358198A4 (en) 2008-03-05
US20060293284A1 (en) 2006-12-28
PL373670A1 (en) 2005-09-05
JP3959348B2 (en) 2007-08-15

Similar Documents

Publication Publication Date Title
US7723319B2 (en) Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same
AU2002230230A1 (en) Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same
US20060052346A1 (en) Nucleoside phosphonate derivatives useful in the treatment of HIV infections
US8193167B2 (en) Pharmacologically active agents containing esterified phosphonates and methods for use thereof
US10702532B2 (en) Nucleotide analogs
US6479673B1 (en) Antiretroviral enantiomeric nucleotide analogs
US8222257B2 (en) Phosphono-pent-2-en-1-yl nucleosides and analogs
US11572377B2 (en) Nucleotide analogs
US20060111324A1 (en) (+)-Ttrans-isomers of (1-phosphonomethoxy-2-alkylcyclopropyl)methyl nucleoside derivatives, process for the preparation of stereoisomers thereof, and use of antiviral agents thereof
CA2224710A1 (en) Phosphonate nucleotide derivatives
HU225970B1 (en) Antiviral acyclic phosphonomethoxyalkyl-substituted alkenyl purine and pyrimidine derivatives, and pharmaceutical preparations containing them
TWI323263B (en) Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same
NZ325704A (en) Nucleotide analogs
Choi et al. Ttrans-isomers of (1-phosphonomethoxy-2-alkylcyclopropyl) methyl nucleoside derivatives, process for the preparation of stereoisomers thereof, and use of antiviral agents thereof

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.)

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.)

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20180525